Priority Area 09: Infectious Disease Including HIV/AIDS

Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. HHSA290201000006C

Prepared by:
ECRI Institute
5200 Butler Pike
Plymouth Meeting, PA 19462

June 2012
Statement of Funding and Purpose
This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

This report’s content should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual topic profiles are developed for technologies and programs that appear to be close to diffusion into practice in the United States. Those reports are sent to various experts with clinical, health systems, health administration, and/or research backgrounds for comment and opinions about potential for impact. The comments and opinions received are then considered and synthesized by ECRI Institute to identify interventions that experts deemed, through the comment process, to have potential for high impact. Please see the methods section for more details about this process. This report is produced twice annually and topics included may change depending on expert comments received on interventions issued for comment during the preceding 6 months.

A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in horizon scanning, assessing the leads for topics, or providing opinions regarding potential impact of interventions.

Disclaimer Regarding 508-Compliance
Individuals using assistive technology may not be able to fully access information in this report. For assistance contact info@ahrq.gov.

Financial Disclosure Statement
None of the individuals compiling this information has any affiliations or financial involvement that conflicts with the material presented in this report.

Public Domain Notice
This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

Preface

The purpose of the AHRQ Healthcare Horizon Scanning System is to conduct horizon scanning of emerging health care technologies and innovations to better inform patient-centered outcomes research investments at AHRQ through the Effective Health Care Program. The Healthcare Horizon Scanning System provides AHRQ a systematic process to identify and monitor emerging technologies and innovations in health care and to create an inventory of interventions that have the highest potential for impact on clinical care, the health care system, patient outcomes, and costs. It will also be a tool for the public to identify and find information on new health care technologies and interventions. Any investigator or funder of research will be able to use the AHRQ Healthcare Horizon Scanning System to select potential topics for research.

The health care technologies and innovations of interest for horizon scanning are those that have yet to diffuse into or become part of established health care practice. These health care interventions are still in the early stages of development or adoption, except in the case of new applications of already-diffused technologies. Consistent with the definitions of health care interventions provided by the Institute of Medicine and the Federal Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs and biologics, medical devices, screening and diagnostic tests, procedures, services and programs, and care delivery.

Horizon scanning involves two processes. The first is identifying and monitoring new and evolving health care interventions that are purported to or may hold potential to diagnose, treat, or otherwise manage a particular condition or to improve care delivery for a variety of conditions. The second is analyzing the relevant health care context in which these new and evolving interventions exist to understand their potential impact on clinical care, the health care system, patient outcomes, and costs. It is NOT the goal of the AHRQ Healthcare Horizon Scanning System to make predictions on the future use and costs of any health care technology. Rather, the reports will help to inform and guide the planning and prioritization of research resources.

We welcome comments on this Potential High Impact report. Send comments by mail to the Task Order Officer named in this report to: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by e-mail to effectivehealthcare@ahrq.hhs.gov.

Carolyn M. Clancy, M.D. Jean Slutsky, P.A., M.S.P.H.
Director Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality

Elise Berliner, Ph.D.
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality
Contents

Executive Summary .................................................................................................................................................. ES-1
  Background .......................................................................................................................................................... ES-1
  Methods .............................................................................................................................................................. ES-1
  Results ............................................................................................................................................................... ES-2
  Discussion .......................................................................................................................................................... ES-3

Hepatitis C Virus Infection Intervention .............................................................................................................. 1
  NS3/4A Protease Inhibitors (Boceprevir and Telaprevir) for Treatment of Chronic Hepatitis C Infection ......... 2

HIV/AIDS Interventions .......................................................................................................................................... 6
  Collaborative Care Model for Treatment of HIV and Comorbid Depression ......................................................... 7
  Emtricitabine/Tenofovir (Truvada) for Prevention of HIV Infection .................................................................. 9
  Routine Anal Pap Smear Screening at HIV Clinics to Prevent Anal Cancer .................................................... 13

Healthcare-Acquired and Bacterial Infection Interventions .................................................................................. 16
  Antimicrobial Copper Surfaces in the ICU for Prevention of Healthcare-Acquired Infections ...................... 17
  Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection ............................................ 20
  Fidaxomicin (Dificid) for Treatment of *Clostridium difficile* Infection .......................................................... 23
  Xpert MTB/RIF Test for Simultaneous Detection and Drug Sensitivity Testing of *Mycobacterium Tuberculosis* ................................................................................................................................. 26

References .................................................................................................................................................................. 29

Figures

Figure 1. Overall High Impact Potential: NS3/4A protease inhibitors .............................................................. 4
Figure 2. Overall High Impact Potential: Collaborative care model for HIV and depression ....................... 8
Figure 3. Overall High Impact Potential: Emtricitabine/tenofovir (Truvada) for prevention of HIV infection .......................................................................................................................... 10
Figure 4. Overall High Impact Potential: Routine anal Pap smear screening at HIV clinics ....................... 14
Figure 5. Overall High Impact Potential: Antimicrobial copper surfaces in the ICU for prevention of HAI’s ....................................................................................................................................... 19
Figure 6. Overall High Impact Potential: Fecal transplantation to treat recurrent *C. difficile* infection .................................................................................................................................................... 22
Figure 7. Overall High Impact Potential: Fidaxomicin for treatment of *C. difficile* infection ....................... 24
Figure 8. Overall High Impact Potential: Xpert MTB/RIF test for detection and drug sensitivity testing of *M. Tuberculosis* ........................................................................................................ 28
Executive Summary

Background

Horizon scanning is an activity undertaken to identify technological and system innovations that could have important impacts or bring about paradigm shifts. In the health care sector, horizon scanning pertains to identifying new (and new uses of existing) pharmaceuticals, medical devices, diagnostic tests and procedures, therapeutic interventions, rehabilitative interventions, behavioral health interventions, and public health and health promotion activities. In early 2010, the Agency for Healthcare Research and Quality (AHRQ) identified the need to establish a national Healthcare Horizon Scanning System to generate information to inform comparative-effectiveness research investments by AHRQ and other interested entities. AHRQ makes those investments in 14 priority areas. For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures, treatments, screening and diagnostics, therapeutics, surgery, programs, and care delivery innovations that address unmet needs. Thus, we refer to topics identified and tracked in the AHRQ Healthcare Horizon Scanning System generically as “interventions.” The AHRQ Healthcare Horizon Scanning System implementation of a systematic horizon scanning protocol (developed between September 1 and November 30, 2010) began on December 1, 2010. The system is intended to identify interventions that purport to address an unmet need and are up to 7 years out on the horizon and then to follow them for up to 2 years after initial entry into the health care system. Since that implementation, more than 11,000 leads about topics have resulted in identification and tracking of more than 900 topics across the 14 AHRQ priority areas and one cross-cutting area.

Methods

As part of the Healthcare Horizon Scanning System activity, a report on interventions deemed as having potential for high impact on some aspect of health care or the health care system (e.g., patient outcomes, utilization, infrastructure, costs) is aggregated twice annually. Topics eligible for inclusion are those interventions expected to be within 0–4 years of potential diffusion (e.g., in phase III trials or for which some preliminary efficacy data in the target population are available) in the United States or that have just begun diffusing and that have completed an expert feedback loop.

The determination of impact is made using a systematic process that involves compiling information on topics and issuing topic drafts to a small group of various experts (selected topic by topic) to gather their opinions and impressions about potential impact. Those impressions are used to determine potential impact. Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the same class are read separately), and then topics in the same class of a device, drug, or biologic are aggregated for discussion and impact assessment at a class level for this report. The process uses a topic-specific structured form with text boxes for comments and a scoring system (1 minimal to 4 high) for potential impact in seven parameters. Participants are required to respond to all parameters.

The scores and opinions are then synthesized to discern those topics deemed by experts to have potential for high impact in one or more of the parameters. Experts are drawn from an expanding database ECRI Institute maintains of approximately 350 experts nationwide who were invited and agreed to participate. The experts comprise a range of generalists and specialists in the health care sector whose experience reflects clinical practice, clinical research, health care delivery, health business, health technology assessment, or health facility administration perspectives. Each expert uses the structured form to also disclose any potential intellectual or financial conflicts of interest (COI). Perspectives of an expert with a COI are balanced by perspectives of experts without COIs. No more than two experts with a possible COI are considered out of a total of the seven or eight
experts who are sought to provide comment for each topic. Experts are identified in the system by the perspective they bring (e.g., clinical, research, health systems, health business, health administration, health policy).

The topics included in this report had scores and/or supporting rationales at or above the overall average for all topics in this priority area that received comments by experts. Of key importance is that topic scores alone are not the sole criterion for inclusion—experts’ rationales are the main drivers for the designation of potentially high impact. We then associated topics that emerged as having potentially high impact with a further subcategorization of “lower,” “moderate,” or “higher” within the potential high impact range. As the Healthcare Horizon Scanning System grows in number of topics on which expert opinions are received, and as the development status of the interventions changes, the list of topics designated as potential high impact is expected to change over time. This report is being generated twice a year.

For additional details on methods, please refer to the full AHRQ Healthcare Horizon Scanning System Protocol and Operations Manual published on AHRQ’s Effective Health Care Web site.

Results

The table below lists the 11 topics for which (1) preliminary phase III data on drugs, phase II or III data on devices and procedures were available, or programs were being piloted; (2) information was compiled by April 15, 2012, in this priority area; and (3) we received six to eight sets of comments from experts between February 2011 and April 26, 2012. (In this priority area, 107 topics were being tracked in the system as of May 2012.) For purposes of the Potential High Impact Interventions Report, we aggregated related topics for summary and discussion (e.g., individual drugs into a class). We present eight summaries of nine topics (indicated below with an asterisk) that emerged as potential high impact on the basis of experts’ comments and their assessment of potential impact. The material on interventions in this Executive Summary and report is organized alphabetically by disease state. Readers are encouraged to read the detailed information on each intervention that follows the Executive Summary.

Priority Area 09: Infectious Disease Including HIV/AIDS

<table>
<thead>
<tr>
<th>Topic</th>
<th>High Impact Potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. *Antimicrobial copper surfaces in the ICU for prevention of hospital acquired infections</td>
<td>High</td>
</tr>
<tr>
<td>2. Bioabsorbable gentamicin surgical implant (CollaRx) to prevent postsurgical infection</td>
<td>No high-impact potential at this time</td>
</tr>
<tr>
<td>3. *Collaborative care model for treatment of HIV and comorbid depression</td>
<td>Lower range of high impact</td>
</tr>
<tr>
<td>4. *Emtricitabine/tenofovir (Truvada) for prevention of HIV infection</td>
<td>High</td>
</tr>
<tr>
<td>5. *Fecal microbiota transplantation to treat recurrent <em>C. difficile</em> infection</td>
<td>High</td>
</tr>
<tr>
<td>6. *Fidaxomicin (Dificid) for treatment of <em>Clostridium difficile</em> infection</td>
<td>High</td>
</tr>
<tr>
<td>7. *NS3/4A protease inhibitor (boceprevir [Victrelis]) for treatment of chronic hepatitis C infection</td>
<td>High</td>
</tr>
<tr>
<td>8. *NS3/4A protease inhibitor (telaprevir [Incivek]) for treatment of chronic hepatitis C infection</td>
<td>High</td>
</tr>
<tr>
<td>9. Peramivir for treatment of influenza</td>
<td>No high-impact potential at this time</td>
</tr>
<tr>
<td>10. *Routine anal Pap smear screening at HIV clinics to prevent anal cancer</td>
<td>Moderately high</td>
</tr>
<tr>
<td>11. *Xpert MTB/RIF test for simultaneous detection and drug sensitivity testing of <em>M. tuberculosis</em></td>
<td>Moderately high</td>
</tr>
</tbody>
</table>
Discussion

Hepatitis C Virus Infection

Hepatitis C virus (HCV) is a major public health concern, the primary cause of death from liver disease, and the leading cause for liver transplantation in the United States. According to the U.S. Centers for Disease Control and Prevention (CDC), an estimated 3.2 million Americans have chronic HCV infection. From 50% to 80% of infected people are reportedly unaware they are infected. Additionally, about 50,000 of the 1 million people with chronic HIV infection in the U.S. are also chronically infected with HCV. Some calculations suggest that HCV-related mortality will continue to increase over the next 2 decades without effective new treatment. Also, total U.S. annual medical costs for HCV-infected people are expected to almost triple, from $30 billion in 2009 to about $85 billion by 2029.

Chronic HCV infection is considered clinically “curable”—that is, the virus can be suppressed to undetectable levels. The current standard of care is an initial regimen of pegylated-interferon alpha-2a (Pegasys®, Hoffmann-La Roche Inc., Basel, Switzerland) and ribavirin (Copegus®, Hoffmann-La Roche), a combination known as IFN/RBV. However, about 60% of patients in whom HCV is diagnosed who undergo and complete the IFN/RBV treatment for 48 weeks do not achieve a viral cure. Additionally, less than 10% of people whose cases are diagnosed and who attempt therapy actually complete it, leaving them at risk for relapse because of the long course of therapy, poor cure rates, and poor quality of life during therapy.

Thus, intensive research has been ongoing, with dozens of drugs in development in new drug classes. The relatively recent explosion in HCV drug development has come about because of effective and efficient in vitro methods that enable developers to quickly screen and evaluate potential candidates.

NS3/4A Protease Inhibitors for Treatment of HCV Infection

- **Key Facts:** In May 2011, two new agents in a new class known as protease inhibitors became the first medications approved in 20 years to treat HCV infection: oral telaprevir (Incivek™, Vertex Pharmaceuticals, Inc., Cambridge, MA) and oral boceprevir (Victrelis™, Merck & Co., Inc., Whitehouse Station, NJ). Researchers reported that these protease inhibitors increased efficacy so that 65% to 75% of patients with the most common genotype, HCV genotype 1, who were given one of these agents in combination with IFN/RBV, achieved a sustained virologic response (referred to in clinical trials as a “clinical cure”). The availability of these new agents could improve treatment outcomes for many patients. However, more options are needed because of side effects and because some populations have been more challenging to treat than others (i.e., African-American patients have lower clinical response than whites to HCV therapy; patients co-infected with HIV or genotype 4 and patients who are prior nonresponders to IFN/RBV with other comorbid conditions, such as nonalcoholic fatty liver disease, need new effective options). However, side effects reported with the new protease inhibitors might affect full patient compliance.

IFN/RBV and telaprevir therapy has caused severe rashes that respond poorly to steroids in some patients; in treatment with boceprevir, a significantly higher incidence of anemia was reported. Physicians must also combine protease inhibitors with other antiviral agents because monotherapy with protease inhibitors has led to drug-resistant HCV strains. Lessons learned from HIV treatment suggest that combination therapy, with several distinct compounds with differing mechanisms of action, are essential to minimize emergence of drug-resistant strains. The IFN/RBV component of an HCV treatment regimen seems to
mitigate development of resistance and is expected to remain a mainstay of treatment in the near term along with its side effects. Additionally patients co-infected with HCV and HIV must be closely monitored for drug interactions, particularly when taking some ritonavir-boosted HIV protease inhibitors in combination with HCV protease inhibitors. Boceprevir has been shown to lower serum concentrations of the HIV drugs, while the HIV protease inhibitors have been shown to lower serum concentrations of telaprevir.

Many companies have been developing strategies to eliminate IFN or IFN/RBV in the treatment regimen, and may include combinations of protease, polymerase inhibitors, NS5A inhibitors, or HCV polymerase inhibitors alone. In anticipation of protease inhibitors, it has been documented that clinicians held up initiating treatment of IFN/RBV-only regimens in HCV-infected patients to enable them to have what clinicians believed would be a better chance of clinical success once protease inhibitors became available. Although many of these patients are now seeking treatment with a protease inhibitor in combination with IFN/RBV, there is evidence that some patients are still waiting for an IFN-free regimen to become available, due to preference or contraindication for existing therapies. Some in the HCV community are hopeful that nucleoside polymerase inhibitors and or/ NS5A inhibitors in some combination may provide an IFN-free regimen with improved efficacy, tolerability and shorter treatment regimen. Many of these drugs are tracked in the horizon scanning system, but have not reported results from a phase III trial as of this writing.

Boceprevir’s average wholesale price is $15.71 per 200 mg capsule, or $5,280 when sold by the package of 336 capsules (a 28-day supply). Merck stated that the wholesale acquisition cost is about $1,100 per patient per week of treatment. Merck has a patient-assistance program to defray costs for those without insurance or whose insurance does not cover the drug.

The current average wholesale price of a course of telaprevir treatment is about four times higher than boceprevir ($117.14 per 375 mg capsule); the company set the average wholesale price at $49,200 for a 12-week regimen, or $4,100 per week.

Our searches of 11 representative private third-party payers that provide online medical coverage policies (i.e., Aetna, Anthem, Blue Cross/Blue Shield Alabama, Blue Cross/Blue Shield Massachusetts, Cigna, HealthPartners, Humana, Medica, Regence, United Healthcare, Wellmark) identified 11 payers that list coverage determinations for protease inhibitors to treat chronic HCV genotype 1 infection. In general, payers cover protease inhibitor therapy for treating chronic HCV infection; however, preauthorization is required, and quantity limits are generally imposed. One third-party payer stated that telaprevir is the preferred brand and that boceprevir is the nonpreferred brand.

**Key Expert Comments:** Overall, experts saw all the protease inhibitors as having significant potential to address the unmet need of effective treatment for chronic HCV infection. They thought that fulfilling this need could provide a large benefit from the public health perspective and that these drugs could significantly reduce morbidity, mortality, cost of chronic infection, and demands on the health care system in the long term. However, they speculated that these benefits might be offset by high costs of protease-inhibitor treatment and the development of adverse events, which would require its own expensive treatment and followup. As the first class of new therapies for HCV treatment in 20 years and the first class of direct-acting antivirals for this condition, NS3/4A inhibitors were expected by experts commenting on this intervention to have a high impact on health care.

**Potential for High Impact:** High
**HIV/AIDS**

HIV infection continues to be a major public health concern, continuously challenging physicians, researchers, and public health officials to find the best practices to contain the epidemic. HIV prevention measures remain crucial in controlling the disease. However, as HIV management has transitioned from a deadly fatal infection to a chronic illness, more attention has shifted toward effectively controlling the infection and the numerous accompanying comorbidities. Three interventions for management of HIV infection have been identified for this report as having high potential impact—one for prevention of HIV infection and the other two for managing comorbidities associated with infection.

**Collaborative Care Model for Comorbid HIV and Major Depressive Disorder**

- **Key Facts:** HIV and major depressive disorder (MDD) frequently co-occur in patients with HIV. MDD is the most common mental illness that these patients experience, yet MDD is both underdiagnosed and undertreated in this patient population. Feelings of severe, persistent sadness and hopelessness can lead to negative behaviors associated with HIV management and treatment adherence, which can lead to disease progression and even increased mortality. According to the U.S. National Institute of Mental Health (NIMH), MDD should be treated as a separate illness for patients with HIV. Common interventions for MDD include psychotherapy and prescription antidepressant medications. NIMH notes that MDD treatment in the context of HIV should be managed by a mental health professional, especially when antidepressant pharmacotherapy is prescribed, to avoid drug interactions.

To improve MDD diagnosis and management as well as HIV outcomes, a collaborative care team consisting of a registered nurse depression care manager (DCM), a clinical pharmacist, and a psychiatrist can be formed with protocols in place to facilitate communication and appropriate treatment. As part of the program, patients with HIV are screened for MDD at the HIV clinic during regular visits. The care team convenes once weekly and can communicate via electronic medical record progress notes. The DCM also communicates with patients via telephone on an ongoing basis to deliver participant education and activation, assesses treatment barriers and possible resolutions, monitors depression symptoms, treats any substance abuse, and provides instruction in self-management. Referrals can be made to specialty mental health care providers at any time. Investigators in one study conducted in three Veterans Affairs clinics reported that patients infected with HIV (n=249) and with depression who were treated with collaborative care were more likely than patients treated with usual care to report treatment response and remission at 6 months. Patients treated with collaborative care reported more depression-free days during a 12-month period than patients treated with usual care. Patients treated with collaborative care had a significant reduction in HIV symptom severity at 6 months and 12 months compared with usual care. In a retrospective analysis, charts from patients (n=124) with HIV and comorbid depression who were referred for depression treatment at a psychiatric facility located within an infectious diseases outpatient clinic were also analyzed. In the post-treatment period, significant reductions in depression and HIV RNA were observed, while significant increases in CD4 T-cell count and antidepressant prescriptions were observed compared with the pretreatment period.

- **Key Expert Comments:** Overall, experts commented that a collaborative care model to treat MDD in patients with HIV could lead to improved diagnosis of MDD in more patients.
with HIV. They believed that better MDD management might lead to improved treatment adherence and improve health outcomes. They also speculated that patients can gain a better understanding of their infection and how to better manage it. Experts pointed out that establishing a collaborative care group might result in the need for additional staff, facilities, and information technology as well communication sessions that might change care processes. In addition, increased diagnosis of MDD is expected to increase demand for mental health services. Experts expected clinicians to accept the intervention due to the minimal training required and the potential to improve treatment adherence and outcomes. Experts were concerned that some patients might not accept the intervention because of a perceived stigma from the diagnosis of depression.

- **Potential for High Impact**: Lower range of high impact

**Routine Anal Pap Screening in HIV Clinics**

- **Key Facts**: Patients with HIV have a higher risk of developing anal cancer, possibly due to impaired T-cell function, yet no national or international guidelines for anal dysplasia screening are available for this patient population. The incidence of anal cancer rates in individuals infected with HIV increased from 19.0 per 100,000 person-years for the period 1992-1995, to 72.2 for 2000-2003. One cohort study showed that as many as 49% of HIV-infected men who have sex with men (MSM) developed high-grade anal dysplasia within 4 years, compared with 17% of MSM not infected with HIV. Additionally, cross-sectional studies revealed anal dysplasia in 26% of women and 34% of men infected with HIV who did not report a history of anal intercourse. Before anal cancer develops, precancerous lesions can usually be detected and excised before progressing to anal cancer.\(^1\) Anal Papanicolaou (Pap) screening incorporated into routine visits for treatment and monitoring at HIV clinics for all patients, regardless of history of anal intercourse, might help reduce the incidence, morbidity, and mortality of anal cancer in patients with HIV.\(^2\) In a pilot study, 82% of HIV-infected patients approached during routine clinic visit agreed to participate in the study requiring an anal Pap smear collection. Fifty-three percent of patients had abnormal cytology results; among those undergoing high-resolution anoscopy with biopsy, 55% of patients had high-grade anal intraepithelial neoplasia, including two cases of carcinoma in situ.

- **Key Expert Comments**: Overall, experts stated a significant unmet need exists for earlier anal cancer detection in patients with HIV. The experts theorized that anal Pap screening is an effective tool to improve patient health outcomes, and screening in HIV clinics could be an effective way to implement standardized processes. Once educated about the importance of screening, patients seem to be receptive to the procedure. However, more studies are needed to fully understand the role that anal Pap screening may have on treatment and survival outcomes in this patient population. A greater body of evidence, once obtained, would help to increase diffusion via clinician acceptance and reimbursement.

- **Potential for High Impact**: Moderately high

**Truvada Combination Therapy for Prophylaxis in Population at High Risk of HIV**

- **Key Facts**: CDC estimates that as many as 50,000 people are newly infected with HIV in the U.S. annually; 61% and 23% of new infections occur in MSM and men who have sex with women, respectively. Women are twice as likely to be infected with HIV through heterosexual contact. In 2011, Truvada® (emtricitabine/tenofovir, Gilead Sciences, Inc., Foster City, CA), in phase III development for preventing HIV infection, gained traction as a
potential option for HIV prophylaxis in high-risk males and females seeking effective prevention against HIV. This was based on researchers’ reports of data from a trial that high-risk MSM who took emtricitabine/tenofovir once daily were 44% less likely to become infected with HIV-1 than MSM given placebo. However, researchers later reported evidence that emtricitabine/tenofovir failed to protect high-risk females from contracting HIV. Experts speculated that the lack of efficacy in protecting women might be due to the drug’s inability to concentrate sufficiently in vaginal tissue, which is where transmission occurs during intercourse, or might be related to problems with treatment adherence. Others hypothesized that in one pre-exposure prophylaxis trial, females may have given their HIV medication to their infected partners. These results dampened some enthusiasm and added to the controversy because treatment adherence has been shown to greatly improve efficacy of prophylactic emtricitabine/tenofovir. Additionally, more recent data from two other pre-exposure prophylaxis studies in serodiscordant couples have shown emtricitabine/tenofovir to be 73% to 78% effective in males and females. Emtricitabine/tenofovir is also controversial because some believe that the costly therapy might only buy time until infection occurs, even if the patient adheres to the recommended treatment regimen. In December 2011, Gilead Sciences, Inc. submitted a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for once-daily emtricitabine/tenofovir for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults. In May 2012, the FDA Antiviral Drugs Advisory Committee recommended approval of emtricitabine/tenofovir for prevention of HIV infection in MSM, uninfected partners of HIV-positive partners, and others at risk of infection through sexual activity. FDA set a decision date of June 15, 2012. The retail cost of a 30-day supply of emtricitabine/tenofovir is roughly $1,100. Our searches found no third-party payers with a coverage determination for PrEP at this time.

Key Expert Comments: Overall, experts commenting on this topic thought that prophylactic use of this drug has a high potential to address an important unmet need in preventing HIV-1 infection in high-risk patients. Currently, no preventive options are available other than abstinence and condom use, which are not employed by all individuals at high risk for infection. Experts thought that emtricitabine/tenofovir could have a significant impact on health promotion by reducing the number of HIV-infected individuals. However, experts noted that early trials have shown that this intervention would not protect everyone who attempts the regimen. Experts speculated that this, combined with high treatment costs and likely high out-of-pocket costs to patients for something that is not a disease (i.e., unprotected sex) and that can be prevented with behavioral interventions, would be controversial as the role of prophylactic emtricitabine/tenofovir evolves.

Potential for High Impact: High

Healthcare-Acquired and Bacterial Infections

Experts identified four interventions as having potential for high impact: antimicrobial copper surfaces fitted to intensive care unit (ICU) equipment to reduce hospital-acquired infections, two treatments for recurrent *Clostridium difficile* infection), and a rapid test to determine whether a patient has a drug-resistant form of tuberculosis.
Antimicrobial copper Surfaces in the ICU for Prevention of Hospital-Acquired Infections

**Key Facts:** About 2 million healthcare-acquired infections (HAIs) are documented in the U.S. annually and result in 100,000 deaths. Additionally, CDC has estimated that HAIs add $28 billion to $45 billion to U.S. health care costs annually. On average, HAIs add an estimated 19.2 hospital days per patient contracting an HAI at a per-patient cost of $43,000. Further, patients contracting an HAI have a 1-in-20 chance of dying if the infection is acquired while hospitalized and a 1-in-4 chance of dying if the infection was contracted in the ICU. According to estimates by the International Copper Association, about 80% of infectious diseases are transferred by touch. Despite common infection-control practices, including hand-washing and frequent surface disinfection, the number of HAIs each year continues to rise. Hospital surfaces in patient rooms, including the ICU, typically consist of stainless steel and plastics that possess no antibacterial properties and serve as fomites for disease transmission between disinfection procedures in many health care settings.

The intrinsic antimicrobial properties of copper and copper alloys (brasses and bronzes) for touch surfaces on hospital hardware and equipment might add another safeguard against disease transmission between cleanings. Antimicrobial Copper (International Copper Association, New York, NY) touch surfaces can be incorporated into a wide variety of components, including bedrails, food trays and carts, handrails, IV poles, sinks, faucets, shower and lavatory components, work surfaces, door handles, grab bars, computer keyboards, equipment adjustment knobs, and face plates. Copper’s antimicrobial properties are purported to remain effective for product’s lifetime. These surfaces are purported to continuously reduce bacterial contamination and achieve 99.9% reduction of gram-negative and gram-positive bacteria within 2 hours of exposure. More than 350 alloys, such as brass and bronze, have been registered to be antimicrobial, providing options to fit various clinical and aesthetic demands. Copper surfaces are purported by the manufacturer association to exert their antibacterial activity in two sequential steps. First, antimicrobial copper is purported to disrupt the integrity of bacterial cell membranes through oxidation and disrupt physiologic functions such as electrostatic potential. Second, antimicrobial copper ions are purported to penetrate compromised cells and alter cell metabolism by interacting with numerous enzymes crucial for normal metabolic activity. Copper surfaces are intended to be used in combination with standard infection control procedures. Studies have shown that antimicrobial copper surfaces can significantly reduce the microbial burden found on surfaces in the ICU as well as reduction in infection rates in patients staying in copper-fitted rooms.

**Key Expert Comments:** Overall, experts commenting on this intervention stated that antimicrobial copper touch surfaces could have a significant impact on reducing HAIs and associated morbidity, mortality, and costs. Although a significant capital investment may be required to retrofit frequently touched surfaces in ICUs, the intervention is expected to quickly accrue savings. Except for a one-time disruption in patient management, antimicrobial copper is not expected to alter hospital operations. Although antimicrobial copper surfaces may reduce pathogens, experts warn that infection rates may not decline as much as expected if an HAI is contracted from bacteria already colonizing the patient’s body and thus was not transmitted from a caregiver’s hand or contaminated fomites.

**Potential for High Impact:** High
Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection

- **Key Facts:** More than 300,000 U.S. hospitalizations are complicated each year by *Clostridium difficile* infections (CDIs), with associated annual costs estimated at $431 million to $3 billion. Recurrent CDI is increasingly common and challenging to treat effectively. About 20% of patients have a recurrence. Vancomycin or metronidazole is commonly used after a second CDI recurrence, but when vancomycin therapy is stopped, up to 60% of these patients develop recurrence, which suggests that other therapeutic options are needed.

Colonicoscopic fecal microbiota transplantation (FMT), or fecal transplantation, is intended to recolonize a patient’s intestinal flora with beneficial bacteria that will “crowd out” or otherwise make the environment in the bowel unfavorable for *C. difficile* colonization. During the colonscopic procedure, healthy donors submit fresh stool on the day of the procedure, which is mixed with saline into a solution and tested for pathogens, including hepatitis A, B, and C; syphilis; and HIV (the exact pathogens depend on the center). Centers collecting and processing the stool also typically screen transplant recipients for similar diseases to prevent disease transmission. Once prepared and tested, the fecal-saline solution is introduced into the intestines by a gastroenterologist using a colonoscope to enter the right cecum, and the rest is introduced distally as the colonoscope is withdrawn. Typically, this procedure is required only once in a patient. Other FMT procedures have also been reported using enemas and nasogastric tubes. Researchers who analyzed more than 77 patients with recurrent CDI from five treatment centers across the U.S. who received FMT reported that CDI was cured in 91% of patients. Other smaller trials have reported similar success rates. Some news reports have stated that facilities offering the procedure inform patients that a 90% success rate can be assumed. The procedure is being implemented in a small number of research and gastrointestinal specialty centers and can be readily adopted at medical facilities because it is not subject to FDA regulation and the material is collected and prepared at the institution. Four registered comparative trials are ongoing in the U.S. and other countries to assess the therapy compared to oral vancomycin in patients with recurrent CDIs.

Specific cost information on the procedure is scarce because it has been performed infrequently by a limited number of clinicians at a small number of centers. Reported costs associated with screening donor blood and stool for contagious agents, preparation of the donor fecal sample, and placement of a nasogastric tube or retention enema tube can exceed $2,500. If the procedure is done by colonoscopy, the average cost of colonoscopy is about $3,000. Screening, collection, and preparation of the stool would be additional costs.

- **Key Expert Comments:** Overall, experts concluded that results from the small number of FMT studies completed thus far are very promising. However, experts were eager to see larger studies to better determine the role of FMT in clinical practice. Experts noted that several societal barriers to acceptance of the procedure and a lack of standardized protocols could slow diffusion; however, they also noted that the severity of recurrent CDI and its impact on patient quality of life might prompt patients to accept the procedure.

- **Potential for High Impact:** High

Fidaxomicin for Treatment of Recurrent *Clostridium difficile* Infection

- **Key Facts:** Fidaxomicin (Dificid™, Optimer Pharmaceuticals, Inc., San Diego, CA) is a narrow-spectrum oral macrolide taken twice daily that is purported to be poorly absorbed by the body, allowing the intervention to exert its activity in the gastrointestinal tract. However,
because fidaxomicin is purported to be highly selective for *C. difficile*, the antibiotic leaves the normal intestinal flora intact. In clinical trials, fidaxomicin has been shown to have similar cure rates to vancomycin but lower rates of recurrence, persistent diarrhea, and death after the course of therapy. In June 2011, FDA approved fidaxomicin for treating *C. difficile*-associated diarrhea. According to one U.S.-based online pharmacy, a 10-day course of fidaxomicin costs about $3,625.23 compared to $1,400.23 for a 10-day course of vancomycin. Our searches of 11 representative private third-party payers that provide online medical coverage policies found seven that list coverage determinations for fidaxomicin for treating *C. difficile*-associated diarrhea. Six payers cover fidaxomicin for members with *C. difficile*-associated diarrhea. However, preauthorization is frequently required and fidaxomicin often has tier 3 or 4 formulary status.

- **Key Expert Comments**: The experts commenting on this topic stated that recurrent CDI can persist for a long time in a patient and be very costly to treat, with high morbidity and mortality. The lack of new medications for the treatment of CDI has created an unmet need for an agent that can treat and minimize recurrent infections. Although fidaxomicin is more expensive than vancomycin, experts expect the antibiotic to be cost-saving if it prevents CDI recurrence. Diffusion of fidaxomicin as a first-line treatment might depend largely on whether patients have prescription drug coverage and formulary status of the drug on the patient’s drug plan.

- **Potential for High Impact**: High

**Rapid Test for Treatment-Resistant TB**

- **Key Facts**: According to the World Health Organization, *Mycobacterium tuberculosis* infection is highly underdiagnosed because of current tuberculosis (TB) testing methods that require weeks to deliver a definitive result. During that time, infected patients are untreated or may be placed on ineffective therapies, thereby continuing to spread TB and creating a significant public health concern. In the U.S., TB prevalence has resurfaced since 1985, attributed mostly to the increase in HIV infection and development of drug-resistant TB organisms. In 2010, the TB rate in the U.S. was 3.6 cases per 100,000 individuals, a slight decrease from 2009. California, Florida, New York, and Texas accounted for half of all new TB cases in 2010. Although TB rates in the U.S. are relatively low, 60% of TB cases in the U.S. occur in patients who were born outside the country. Thus, the need for effective, rapid diagnostics and new treatments to address resistant strains that are emergent globally is significant. The Xpert MTB/RIF (M. tuberculosis/rifampicin) test (Cepheid, Sunnyvale, CA) is a nucleic-acid-based test that is run on Cepheid’s GeneXpert® real-time polymerase chain reaction (PCR) system. The test is intended to simultaneously detect the presence of *M. tuberculosis* complex species and determine whether the identified bacterium is susceptible to rifampicin, a first-line therapy for TB. The assay is intended to yield results in about 2 hours, which would enable relatively rapid initiation of treatment. The test is available in the U.S. as a research-use-only reagent; U.S. marketing approval of a test kit is expected by 2013 or 2014.

- **Key Expert Comments**: Overall, experts thought that this test had potential as a rapid, sensitive, and specific diagnostic test to address the unmet need for more rapid diagnosis and better initial management of TB, thus improving patient health outcomes and reducing spread of disease. By knowing the patient’s TB status when the patient leaves the physician’s office, more appropriate treatment could be given and proper infection control measures could begin to be implemented. However, one limitation of the Xpert MTB/RIF test is that it tests only for resistance to rifampin, which is a common first-line antibacterial
agent. Susceptibility to other agents would still have to be guided by traditional testing methods. Nevertheless, the Xpert MTB/RIF test could replace other PCR methods of detection and provide an improved approach to diagnosis and treatment for smaller health care facilities, such as rural or public access clinics, which may have problems with followup.

- **Potential for High Impact**: Moderately high
Hepatitis C Virus Infection Intervention
NS3/4A Protease Inhibitors (Boceprevir and Telaprevir) for Treatment of Chronic Hepatitis C Infection

Unlike infections with HIV and hepatitis B virus, chronic hepatitis C virus (HCV) infection is considered “curable.” However, approximately 60% of people who undergo treatment with the current standard of care, an initial regimen of IFN/RBV for 48 weeks, do not achieve a sustained virologic response (SVR) or viral cure, leaving them at risk for future liver disease. Because of recent advances allowing researchers to screen HCV drugs more effectively in vitro, many new HCV drug therapies are in clinical development. The class of agents furthest along in development is the direct-acting antiviral NS3/4A protease inhibitor. The protease activity of the HCV NS3 protein is required for HCV maturation and replication. The NS4A peptide functions as a cofactor for NS3 and plays a key role in increasing the processing rate of the viral polypeptide. Additionally, the activity of NS3/4A protease appears to be associated with HCV’s ability to evade the host’s innate immune response to the virus, further demonstrating the importance of NS3/4A as a target for HCV therapy.

Inhibition of NS3/4A results in production of immature, noninfectious HCV virions, leading to SVR.

Boceprevir

Boceprevir (Victrelis™, Merck & Co., Inc., Whitehouse Station, NJ) is orally administered. In May 2011, the U.S. Food and Drug Administration (FDA) granted marketing approval for the treatment of chronic HCV genotype 1 infection in combination with IFN/RBV, which is a combination of pegylated-interferon alpha-2a (Pegasys®, Hoffmann-La Roche Inc., Basel, Switzerland) and ribavirin (Copegus®, Hoffmann-La Roche). Boceprevir was the first new drug approved for the treatment of HCV in 20 years. It has been used in clinical trials at a dosage of 800 mg three times per day, although doses may vary.

In one of several phase III clinical trials, treatment-naive patients with chronic HCV-1 (n=1,099) were given boceprevir in combination with IFN/RBV in one of two treatment regimens (48 weeks of boceprevir plus IFN/RBV or 24 weeks of boceprevir plus IFN/RBV for 24 or 48 weeks) or 48 weeks of placebo with IFN/RBV. Overall, SVR at 48 weeks was achieved by 65% of patients in the boceprevir groups compared with 38% of patients in the control group with no significant difference observed between the two boceprevir groups. In a second phase III trial, treatment-experienced patients (n=404) with chronic HCV-1 whose infection persisted despite prior treatment with IFN/RBV were given boceprevir in combination with IFN/RBV or placebo in combination with IFN/RBV. In the boceprevir group, 66% of patients achieved SVR at 48 weeks compared with 21% of patients in the control group.

Boceprevir therapy costs an estimated $1,100 per week (wholesale acquisition cost). The therapy’s total cost depends on whether response-guided therapy is appropriate for a patient, which would shorten the treatment duration from 44 weeks to 28 or 36 weeks. Merck has a patient-assistance program to defray costs for those without insurance or whose insurance does not cover the drug.

Our searches of 11 representative private third-party payers that provide online medical coverage policies (i.e., Aetna, Anthem, Blue Cross/Blue Shield Alabama, Blue Cross/Blue Shield Massachusetts, Cigna, HealthPartners, Humana, Medica, Regence, United Healthcare, Wellmark) identified 11 payers that list coverage determinations for protease inhibitors to treat chronic HCV genotype 1 infection. In general, payers cover boceprevir therapy for treating chronic HCV infection; however, preauthorization is required and monthly quantity limits are generally imposed.
One third-party payer stated that telaprevir (see below) is the preferred brand and that boceprevir is the nonpreferred brand.18

**Telaprevir**

Telaprevir (Incivek™, Vertex Pharmaceuticals, Inc., Cambridge, MA) is orally administered and received FDA approval in May 2011 for treating chronic HCV genotype 1 infection in combination with IFN/RBV.25 Telaprevir was administered at 750 mg every 8 hours in clinical trials and is being evaluated for 1,125 mg twice-daily dosing.26

In a phase III trial, treatment-naive patients infected with HCV genotype 1 (n=1,088) were given telaprevir in one of two dose regimens in combination with IFN/RBV or placebo.4 After receiving a 12-week telaprevir-based combination regimen followed by IFN/RBV alone, 75% of patients achieved an SVR at 24 weeks. After receiving an 8-week telaprevir-based combination regimen, followed by IFN/RBV alone, 69% of patients achieved an SVR. In the control arm, 44% of patients achieved an SVR after 48 weeks of IFN/RBV.4 In a second phase III trial, treatment-experienced patients with genotype-1 HCV whose disease had failed to achieve an SVR with prior IFN/RBV therapy (n=663) were given telaprevir or placebo in combination with IFN/RBV.27 At 24 weeks, 65% of patients given telaprevir achieved an SVR compared with 17% in the control group. Telaprevir has also been evaluated in phase II trials as part of an interferon-free regimen in combination with VX-222 (Vertex Pharmaceuticals), a non-nucleoside HCV NS5B polymerase inhibitor, and ribavirin.28 Interim data have shown undetectable HCV in 83% of patients at week 12.28

Currently, nine other HCV protease inhibitors are being tracked in the Horizon Scanning System that have not yet reported phase III data. These interventions will continue to be monitored for at least 2 years from the point of diffusion of boceprevir and telaprevir to determine whether the drugs in development add any benefit or risk compared with drugs already approved in this class.

Telaprevir, when added to current IFN/RBV, is expected to double the treatment cost. The current average wholesale price is about $117 per 375 mg capsule; the company set the price at $49,200 for a 12-week regimen.12 The company introduced a copay assistance program for patients who have to pay out of pocket for telaprevir irrespective of income (Co-pay Assistance Program). Patients with government insurance are not eligible for this benefit.29

**Clinical Pathway at Point of This Intervention**

Patients who test positive for anti-HCV antibodies and HCV RNA may be considered to have acute or chronic HCV infection, depending on the context. Additionally, a patient who tests negative for anti-HCV antibodies and positive for HCV RNA might be chronically infected if immunosuppressed.30 Subsequent HCV genotype testing is performed to determine the therapy regimen and the likelihood of a positive clinical outcome.30 Rest and hydration are typically prescribed. In 2011, the American Association for the Study of Liver Diseases updated its clinical practice guidelines to recommend treating patients with HCV genotype 1 infection with a protease inhibitor (boceprevir or telaprevir) in combination with the previous standard of care, IFN/RBV.31
Overall, experts commenting on this intervention saw the NS3/4A protease inhibitors as having significant potential to address the unmet need of effective treatment for chronic HCV infection. They stated that fulfilling this need could provide a large benefit from the public health perspective and that these drugs could significantly reduce morbidity, mortality, cost of chronic infection, and demands on the health care system in the long term. However, they speculated that these benefits might be offset by high costs of protease inhibitor treatment and the development of adverse events, which would require its own expensive treatment and followup and could lead to treatment discontinuation. As the first class of new therapies for HCV-infection treatment in 20 years and the first class of direct-acting antivirals for this condition, experts commenting on these drugs expected NS3/4A inhibitors to have a higher potential impact on health care, especially if they were eventually part of an IFN-free regimen. Based on this input, our overall assessment is that this intervention is in the higher end of the high-potential-impact range.

Results and Discussion of Comments

Seven experts, with research, clinical, and health systems backgrounds, commented on this intervention. Overall, these experts agreed that current treatment with IFN/RBV was ineffective in most patients, resulting in significant morbidity, mortality, and costs. The current ineffective therapy regimens present a significant unmet need for better treatment strategies for chronic HCV infection. Additionally, experts generally concurred that the underlying theory for the protease inhibitors is theoretically sound. Experts were relatively certain that NS3/4A protease inhibitors have the potential to greatly improve health outcomes, although some experts still interpreted these therapies as additive to IFN/RBV because the approved regimens of telaprevir and boceprevir include IFN/RBV. However, one expert representing a research perspective was concerned about the frequency of adverse events observed with protease inhibitors in combination with IFN/RBV and stated, “if you survive the treatment you could be cured.”

Some experts stated that patients with HCV are disproportionately members of underserved populations. Additionally, African-American patients have a higher incidence of HCV but are less likely to respond to therapy with IFN/RBV only. Thus protease inhibitor therapy may improve outcomes for these patients and reduce health disparities. Dissenting experts stated that the high cost of protease inhibitors and the need for regular IFN injections can represent significant barriers for patients who already have limited access to care and could increase health disparities.

Experts who generally interpreted HCV protease inhibitors as add-on therapies also did not think these treatments would significantly shift treatment or management models. Although patients and clinicians are eager to have new treatment options with increased SVR rates, physician acceptance is expected to be influenced by adverse events and avoiding drug interactions while patients are taking HCV therapy. One clinical expert stated that the ability to manage adverse events will be a crucial factor determining continued patient acceptance of these new agents.
As an adjunctive therapy, protease inhibitors are expected to add significantly to the already high costs of HCV therapy. However, some experts suggested that costs could be offset by reduced duration of therapy. Effective treatment could also reduce the long-term costs of complications such as cirrhosis and liver failure associated with IFN/RBV inefficacy or nontreatment.

Overall, experts stated protease inhibitors have significant potential to address the unmet need for effective treatment for chronic HCV infection. By significantly increasing SVR rates, protease inhibitors are expected to reduce morbidity, mortality, cost of chronic infection, and demands on the health care system in the long term. However, experts speculated that these benefits might be mitigated by high costs of protease inhibitor treatment and the development of adverse events, which would require its own expensive treatment and followup and could lead to treatment discontinuation.
HIV/AIDS Interventions
Collaborative Care Model for Treatment of HIV and Comorbid Depression

Major depressive disorder (MDD) is a psychiatric condition characterized by severe, persistent feelings of sadness and hopelessness that interfere with routine daily activities such as work, sleep, or study. MDD is the most common mental illness that patients with HIV experience, yet MDD is both underdiagnosed and undertreated in this patient population. Patients with comorbid MDD and HIV are likely to have accelerated HIV disease progression, decreased immune functioning, increased failure to adhere to HIV medication regimens, and increased risk of mortality. Because MDD is a modifiable risk factor for HIV progression, effective MDD treatment might improve self-management, adherence behaviors, and HIV outcomes.

Using a collaborative care model might facilitate collaboration between primary care and specialty mental-health-care providers to improve depression diagnosis, care, and treatment outcomes. The model could also allow patients to receive care in more accessible and less stigmatizing settings. Collaborative care models have been successfully used in patients with depression (without HIV comorbid), depression and diabetes, and depression and cancer.

The intervention as implemented in the Veterans Affairs health care system (HIV Translating Initiatives for Depression into Effective Solutions [HITIDES]) involves use of an HIV-specific depression care team consisting of a registered nurse depression care manager (DCM), a clinical pharmacist, and a psychiatrist. As part of the program, patients with HIV are screened for MDD at the HIV clinic during regular visits. The care team convenes once weekly (or additionally as needed) and makes treatment suggestions to HIV treating and mental health clinicians via electronic medical record progress notes. The DCM also communicates with patients via telephone on an ongoing basis (i.e., every two weeks, then monthly), delivering the following intervention components: participant education and activation, assessment of treatment barriers and possible resolutions, monitoring of depression symptoms and substance abuse, and instruction in self-management. At any time during the intervention, HIV health care providers are free to refer patients directly to specialty mental-health-care providers.

In an analysis of patients infected with HIV (n=249) and with MDD, patients were randomly assigned to the intervention (HITIDES; n=123) and to usual care (n=126). Patients treated through the collaborative care model were more likely than patients treated with usual care to report treatment response (33.3% vs. 17.5%; odds ratio, 2.50; 95% confidence interval [CI], 1.37 to 4.56) and remission (22.0% vs. 11.9%; 2.25; 95% CI, 1.11 to 4.54) at 6 months but not 12 months. Patients treated through the collaborative care reported more depression-free days during the 12 months than patients treated with usual care (beta = 19.3; 95% CI, 10.9 to 27.6; p<0.001). Patients treated through collaborative care had a significant reduction in HIV symptom severity at 6 months compared with patients treated with usual care (beta = -2.6; 95% CI, -3.5 to -1.8; p<0.001) and 12 months (beta = -0.82; 95% CI, -1.6 to -0.07; p = 0.03).

Current Approach to Care

According to the U.S. National Institute of Mental Health (NIMH), MDD should be treated as a separate illness for patients with HIV. Common interventions for MDD include psychotherapy and prescription antidepressant medications (e.g., selective serotonin reuptake inhibitors), which NIMH declares generally well-tolerated and safe for people with HIV. NIMH notes that MDD treatment in the context of HIV should be managed by a mental health professional, especially when antidepressant pharmacotherapy is prescribed, so that drug interactions can be avoided. Use of a collaborative care model is intended to facilitate this collaboration between mental health...
specialists and clinicians treating patients for HIV to improve depression and HIV treatment outcomes.  

Figure 2. Overall High Impact Potential: Collaborative care model for HIV and depression

Overall, experts commenting on this intervention thought a collaborative care model to treat MDD in patients with HIV might lead to improved diagnosis of MDD in more patients with HIV. Better management of MDD is expected to improve treatment adherence and health outcomes. Effective MDD treatment might also enable patients to gain a better understanding of their infection and how to better manage it. Establishing a collaborative care group might require additional staff, facilities, and information technology as well communication sessions that, in turn, might change care processes. Increased diagnosis of MDD is expected to increase demand for mental health services. Some experts stated that an onsite collaborative care model would be more likely to reduce barriers to care. Based on this input, our overall assessment is that this intervention is in the lower end of the high-potential- impact range.

Results and Discussion of Comments

Seven experts, with clinical, research, and health systems backgrounds, commented on this intervention. Overall, the experts agreed that HIV and MDD are comorbid conditions with poor treatment outcomes that together can exacerbate both of these conditions. Use of a collaborative care model that can effectively manage both conditions simultaneously improve treatment outcomes better than if the conditions were diagnosed and treated separately. In addition, most of the experts agreed that combining mental health services with HIV care, which frequently affects underserved groups, might improve diagnosis rates and access to care. However, coordinating care between two separate sites was seen by two experts with research and clinical perspectives as potentially increasing disparities for patients with poor access to reliable transportation.

Establishing a collaborative care model for treating HIV and MDD could require the need for additional staff, facilities, and information technology as well as communication sessions, and these requirements could change processes of care. By increasing MDD diagnosis rates, experts thought mental health services would be in greater demand. Third-party payers will also have added costs brought about by the increased number of patients seeking mental health treatment. Some cost offset from the program might be achieved through better adherence to antiretroviral therapy and improved treatment outcomes. One expert with a clinical perspective stated the patients with depression frequently use additional medical resources; thus, effective treatment could reduce this demand in the longer-term.

Clinicians are expected to accept this model due to the minimal training required to implement the program and the potential to increase treatment adherence. While some experts thought many patients would be receptive to the program, they pointed out that some patients might be reluctant because of concerns about the stigma of a depression diagnosis. More data will be needed to fully understand the benefits of this collaborative care model.
Emtricitabine/Tenofovir (Truvada) for Prevention of HIV Infection

An estimated 1.2 million people in the United States are living with HIV infection, and 20% of those individuals are unaware of their HIV status. The U.S. Centers for Disease Control and Prevention (CDC) estimates that as many as 50,000 people are newly infected with HIV in the U.S. annually; 61% and 23% of new infections occur in men who have sex with men (MSM) and women, respectively, and women are twice as likely as men to be infected with HIV through heterosexual contact. One estimate of the HIV transmission risk during receptive anal sex without a condom—the highest-risk sexual activity—indicates that it may be as high as 3% to 5% for each occurrence. The risk is estimated to be lower for receptive vaginal intercourse and even lower for oral sex, each in the absence of a latex barrier (condom or dental dam). Although no single sexual exposure carries a high risk of contagion, HIV infection can occur following the first sexual exposure; therefore, use of latex barriers during each sexual encounter is recommended. Although behavior-change programs have resulted in dramatic reductions in HIV transmission in the U.S., there remains no truly effective means to prevent HIV infection among populations at high risk for infection, including male prostitutes who have sex with men. Pre-exposure chemoprophylaxis (i.e., pretreating uninfected individuals at risk for HIV infection with antiretroviral therapies [ARTs]) is emerging as a potential mechanism for reducing HIV transmission. Evidence is mounting to suggest that ART, taken regularly, may prove effective in reducing risk of HIV infection.

Emtricitabine/tenofovir (Truvada®, Gilead Sciences, Inc., Foster City, CA), which received FDA approval in 2004 for treating HIV, is being evaluated for preventing HIV in adults. According to CDC, many researchers believe that the daily use of an antiviral drug such as emtricitabine/tenofovir is one of the most important new prophylactic measures under investigation for HIV and could help decrease HIV infection in high-risk individuals. Emtricitabine/tenofovir is a once-daily oral combination ART consisting of two HIV nucleoside reverse transcriptase inhibitors, emtricitabine 200 mg (Emtriva®, Gilead Sciences, Inc., Foster City, CA) and tenofovir disoproxil fumarate 300 mg (Viread®, Gilead Sciences). Nucleoside reverse transcriptase inhibitors suppress replication of retroviruses by blocking the activity of HIV-1 reverse transcriptase. This results in premature termination of viral DNA replication.

In the Preexposure Prophylaxis Initiative (iPrEx) trial, HIV-seronegative men or transgender women who have sex with men (n=2,449) were prophylactically given emtricitabine/tenofovir or placebo once daily. The prophylactic use of emtricitabine/tenofovir was shown to lead to a 44% reduction in the incidence of HIV (95% CI, 15 to 63; p=0.005). In another trial, daily prophylactic use of emtricitabine/tenofovir failed to prevent HIV-1 infection in high-risk women. The study was stopped early due to lack of efficacy. The results prompted a warning to doctors from CDC because there have already been reports of women using the drug off-label for HIV prevention.

In a different trial of HIV-1-uninfected heterosexual men and women in Botswana 18 to 39 years of age (n=1,219), daily prophylactic use of tenofovir/emtricitabine reduced the risk of acquiring HIV infection by roughly 63% compared with placebo.

An additional analysis that excluded HIV infections that occurred more than 30 days after a participant’s last reported drug dose was conducted because these individuals could not have been taking study pills at the time of infection. In this analysis, tenofovir/emtricitabine reduced the risk of HIV infection by 78% compared with placebo.

In a another trial examining HIV-1 serodiscordant heterosexual couples in Kenya and Uganda (n=4,758), patients who took daily prophylactic tenofovir or tenofovir/emtricitabine had an average 62% (p=0.0003) and 73% (p<0.0001) fewer HIV infections, respectively, than those who received placebo.
Researchers caution that long-term users of emtricitabine/tenofovir should be monitored for potential side effects. Decline in renal function and proteinuria may be related to long-term use of emtricitabine/tenofovir, especially in African Americans. In June 2011, a letter from the AIDS Healthcare Foundation, signed by 55 physicians, was sent to FDA urging the regulatory body not to approve emtricitabine/tenofovir for HIV-1 pre-exposure prophylaxis (PrEP) even before all data are analyzed from ongoing clinical trials. The letter cited lack of efficacy in the iPrEx trial, lack of “real-world” adherence data, and potential “risk compensation” where patients may engage in riskier behavior than they would without the drug. However, the letter supported an individual physician’s choice to prescribe the drug off-label, which the group thought should alleviate the pressure on FDA to approve the drug prematurely.

In December 2011, Gilead Sciences, Inc., submitted a supplemental New Drug Application to FDA for once-daily emtricitabine/tenofovir for PrEP to reduce the risk of HIV-1 infection among uninfected adults. In February 2012, FDA granted the application priority review status. In May 2012, the FDA Antiviral Drugs Advisory Committee recommended approval of emtricitabine/tenofovir for preventing HIV infection in MSM, uninfected partners of HIV-positive partners, others at risk of infection through sexual activity. FDA has set a decision date of June 15, 2012.

The retail cost of a 30-day supply of emtricitabine/tenofovir is roughly $1,100. Our searches were unable to find any third-party payers with a coverage determination for PrEP. According to the manufacturer, patients with insurance who are prescribed emtricitabine/tenofovir for treating chronic HIV infection commonly have a $10 copay.

Clinical Pathway at Point of This Intervention

According to clinical practice guidelines, the most reliable way to avoid HIV transmission is abstinence from sexual contact or to be in a long-term, mutually monogamous relationship with an uninfected partner. For those entering a monogamous relationship, HIV screening before initiating sex may reduce the risk of future HIV transmission. Male latex condoms are also highly effective at preventing HIV-1 transmission. In people with latex allergy, nonlatex male condoms made of polyurethane or other synthetic material provide protection against HIV equal to that of latex condoms. Emtricitabine/tenofovir is a combination ART under clinical development for the prevention of HIV-1 transmission in patients at high risk for HIV infection.

Figure 3. Overall High Impact Potential: Emtricitabine/tenofovir (Truvada) for prevention of HIV infection

Overall, experts commenting on this intervention thought that prophylactic use of this drug has high potential to address an important unmet need in preventing HIV-1 infection in high-risk patients. Currently, no preventive options are available other than abstinence and condom use, which are not used by all high-risk individuals. Experts thought that emtricitabine/tenofovir could have a large impact on health promotion by reducing the number of HIV-infected individuals. However, experts cited the early trials that have shown this intervention would not protect everyone.
who attempts the regimen. This, combined with high treatment costs and likely high out-of-pocket costs to patients for something that is not a disease (i.e., unprotected sex) and that can be prevented with behavioral interventions, would be controversial as the role of prophylactic emtricitabine/tenofovir evolves. Based on this input, our overall assessment is that this intervention is in the higher end of the high-potential-impact range.

**Results and Discussion of Comments**

Seven experts, with research, clinical, and health systems backgrounds, commented on this intervention. Some expert comments were received before the announcement of one trial’s results that emtricitabine/tenofovir failed to protect women at high risk from contracting HIV-1, and other comments were received after that announcement.

All experts concurred about the significant unmet need for new interventions to prevent HIV-1 transmission among high-risk individuals. Experts agreed that the underlying theory of prophylactic emtricitabine/tenofovir is sound because the therapy has already been shown to be highly effective in controlling HIV-1 replication in infected individuals. In general, experts were somewhat confident that daily emtricitabine/tenofovir use could significantly improve health outcomes. However, one expert with a health systems perspective expressed concern that getting a high-risk individual to take any medication daily for any reason would be a challenge. It was also suggested that a 44% efficacy rate might be evidence of the drug’s potential to offer only short-term efficacy.

Expert opinions were mixed about whether emtricitabine/tenofovir would increase understanding of HIV, its treatment, management, and care models. Some experts thought that the drug would bring no change in understanding these issues because this prophylactic treatment is not a far step from postexposure prophylaxis. Other experts thought that prophylactic emtricitabine/tenofovir use would shift care models from treatment to prevention of HIV-1. Physicians would need to know who needs to be prescribed prophylactic antiretroviral therapy (ART) and may need additional training to properly implement this drug as a preventive measure. One expert with a health systems perspective thought that this would involve a learning curve for physicians. One clinical expert stated that if physicians now have to determine who is at high risk for HIV-1 infection, it might increase the time needed for each patient visit. Experts also noted that prophylactic ART might reduce demands on the health care system by reducing the number of patients chronically infected with HIV-1. One expert with a research perspective stated that healthy individuals would now be considered “patients” and would have to be monitored for treatment side effects. One clinical expert stated that there could be a need to create a venue to treat the condition “unsafe sex.” Two clinical experts also stated that through prophylactic use of ART we could learn more about what the side effects of the drugs are versus actual HIV-1 pathology.

Some disagreement arose among experts regarding the impact of emtricitabine/tenofovir on costs. Two experts with research backgrounds stated that the costs would be high but offset in part because of a reduced number of patients who would contract HIV and need treatment. Another expert representing a health systems perspective stated that the costs of preventing HIV-1 infection could be half the lifetime costs of treating HIV-1 infection. Another expert representing a health systems perspective was alarmed by the high per-person cost of prophylactic ART relative to condoms, potentially posing a strong impediment to acceptance of, adherence to, or payer coverage for the regimen.

Cost considerations aside, prophylactic ART would be met with strong enthusiasm from many patients and clinicians, experts thought; however, other barriers to acceptance may include the frequency of adverse events and the need for complete adherence to the regimen for maximum efficacy.
One expert with a health systems perspective stated that there will always be physicians who support only lifestyle modification for diseases such as HIV-1. An expert with a research perspective stated that regulatory approval would be needed for many physicians to fully accept this intervention, which could be hampered by early reports of inefficacy in women. This expert also stated that prophylactic use of the drug might spark controversy because of the debate about efficacy in women, and because some patients might engage in riskier behavior because they feel safer after using the drug. Another clinical expert stated that use of an expensive medication because of a failure of behavioral interventions might be highly controversial.
Routine Anal Pap Smear Screening at HIV Clinics to Prevent Anal Cancer

Patients with HIV have a higher risk of developing anal cancer, possibly due to impaired T-cell function, yet no national or international guidelines for anal dysplasia screening are available for this patient population. The incidence of anal cancer in people infected with HIV increased from 19.0 per 100,000 person-years for the period 1992–1995 to 72.2 for the period 2000–2003. One cohort study showed that as many as 49% of HIV-infected MSM developed high-grade anal dysplasia within 4 years, compared with 17% of MSM not infected with HIV. Before anal cancer develops, precancerous lesions can usually be detected and excised before progressing to anal cancer. Anal Pap screening incorporated into routine visits for treatment and monitoring at HIV clinics for all patients, regardless of history of anal intercourse, might help reduce the incidence, morbidity, and mortality of anal cancer in patients with HIV.

A pilot screening program for anal intraepithelial neoplasia in HIV-1 positive patients attending the Miami Veteran’s Affairs HIV clinic was developed because for many patients with HIV-1, HIV clinics are the only place where they receive routine care, and these facilities do not have the infrastructure and processes in place to perform routine anal Pap screening in a patient population that is at increased risk for anal cancer. Physicians and nurse practitioners are trained to perform specimen collection by watching a DVD. Specimen collection and cytology reading for an anal Pap smear are similar to those for a cervical Pap smear. Anal Pap smears are collected using the ThinPrep® system (Hologic, Inc., Bedford, MA). Anal cytology is performed, and all samples are read by a pathologist.

In the mentioned pilot study, 82% of HIV-patients approached during routine clinic visit agreed to participate in the study requiring an anal Pap smear collection. Fifty-three percent of patients had abnormal cytology results, and among those undergoing high-resolution anoscopy with biopsy, 55% had high-grade anal intraepithelial neoplasia, including two cases of carcinoma in situ. According to investigators, anal cytology was well accepted, and incorporating it into HIV primary care practice is feasible.

Current Approach to Care

Anal cancer can be detected as part of a digital rectal examination, which is typically part of a routine pelvic exam for women and can occur during regular prostate screening for men older than 50 years of age. However, patients not in these populations may not receive routine screening for anal cancer. The American Cancer Society states that some experts recommend anal cytology (Pap) screening every 2–3 years in patients at high risk for abnormal anal cytology, including MSM (homosexual and bisexual men), women who have had cervical or vulvar cancer, patients with HIV, and organ transplant recipients. If an abnormality is discovered during screening, anal cancer can be diagnosed using various methods, including endoscopy, anoscopy, and rigid proctosigmoidoscopy, followed by biopsy and diagnostic imaging to determine the extent of disease progression. Anal cancer is usually treated with a combination of surgery, radiation, and chemotherapy. Patients with HIV frequently receive routine care only at HIV clinics. Some clinical investigators have proposed that patients attending HIV clinics for routine treatment and monitoring can be screened for anal cancer with anal Pap smears to reduce the incidence of anal cancer in this population.
Overall experts commenting on this intervention noted a significant unmet need for earlier anal cancer detection in patients with HIV. The experts theorize that anal Pap screening is an effective tool to improve patient health outcomes, and screening in HIV clinics may be an effective way to implement standardized processes. Once educated on the importance of screening, patients are receptive to the procedure. However, more studies are needed to fully understand the role that anal Pap screening could have on treatment and survival outcomes in this patient population. Experts noted that a larger body of evidence that demonstrated a benefit for this approach would help to increase diffusion via clinician acceptance and reimbursement. Based on this input, our overall assessment is that this intervention is in the moderate high-potential-impact range.

**Results and Discussion of Comments**

Seven experts, with clinical, research, and health systems backgrounds, offered perspectives on this intervention. Overall, the experts agreed the burden of anal cancer in patients with HIV has increased and that a significant unmet need exists to detect these malignancies early to improve treatment outcomes. If these patients do not receive regular care in another setting, screening for anal cancer in HIV clinics could be appropriate. However, some of the experts felt too little evidence existed to determine how effective anal Pap screening would be in reducing the burden of these cancers and how the cost-savings would compare to that of cervical cancer prevention. Some disagreement arose regarding the impact of anal Pap screening at HIV clinics. Anal Pap smears are generally considered experimental and are not expected to be covered by third-party payers. However, because many patients with HIV have poor access to care, low-cost routine anal cancer screening, regardless of third-party payment, might improve access to care in a population at increased risk of developing anal cancer.

If further studies show anal Pap screening to significantly improve survival, experts thought it could shift health care delivery infrastructure and management from chemotherapy, radiation, and surgery more frequently to early detection of precancer and excision with improved outcomes. Additionally, staff would have to be trained on obtaining and handling specimens and counseling patients with abnormal anal Pap results, and processes would have to be put into place to set alerts every 2-3 years that screening is needed.

If shown to significantly improve survival in patients with HIV, experts thought anal Pap screening would likely be accepted by clinicians; however, some resistance may arise because many other comorbidities exist that clinicians must be aware of when treating patients with HIV; thus, anal Pap screening may seem like “one more thing” clinicians must be concerned with, which takes time and resources. One expert representing a health systems perspective stated that barriers to physician acceptance would include lack of high-resolution anoscopy equipment for followup, lack of consensus regarding the role of anal Pap screening for anal cancer detection, and lack of reimbursement. However, this expert also stated that the New York State Department of Health AIDS Institute recommends annual screening in HIV-positive MSM. Based on the data available,
when patients are aware of their increased risk of anal cancer, they become receptive to screening. Anal Pap screening is expected to cost approximately $45 to $60 per test, which may be affordable for patients with no insurance; some costs will be incurred by HIV clinics to implement training for testing. In some studies, anal cancer rates have been higher than some historical cervical cancer rates, which suggests the screening in this population would be cost-saving to the health care system over time.

Overall, experts stated, a significant unmet need remains for earlier anal cancer detection in patients with HIV. The experts theorize that anal Pap screening could be an effective screening tool to improve patient health outcomes, and screening in HIV clinics may be an effective way to implement standardized processes. However, more studies are needed to fully understand the role that anal Pap screening would have on treatment and survival outcomes in this patient population. A greater body of evidence would help increase diffusion via clinician acceptance and procedure reimbursement.
Healthcare-Acquired and Bacterial Infection Interventions
Antimicrobial Copper Surfaces in the ICU for Prevention of Healthcare-Acquired Infections

Healthcare-associated infections (HAIs) are a significant cause of mortality, morbidity, and added cost in the U.S. health care system. According to estimates by the International Copper Association, about 80% of infectious diseases are transferred by touch. About 2 million HAIs are documented in the U.S. annually and result in 100,000 deaths. In addition, CDC estimates that HAIs add between $28 and $45 billion to annual U.S. health care costs. On average, HAIs add an estimated 19.2 hospital days and $43,000 in additional costs for each patient who contracts an HAI. Further, patients contracting an HAI have a 1-in-20 chance of dying if the infection is acquired while hospitalized and a 1-in-4 chance of mortality if the infection is contracted in the ICU. Hospital surfaces in patient rooms, including the intensive care unit (ICU), typically consist of stainless steel and plastics that purportedly possess no antibacterial properties and serve as fomites for disease transmission between disinfection procedures in many health care settings. In some cases, these surfaces can be colonized with live microbes for days or weeks, providing a contamination source to the hands and equipment of health care workers, professionals, visitors, and patients. The intrinsic antimicrobial properties of copper and copper alloys (brasses and bronzes) for touch surfaces on hospital hardware and equipment could add another safeguard against disease transmission between cleanings.

Antimicrobial Copper (International Copper Association, New York, NY) touch surfaces can be incorporated into a wide variety of components, including bedrails, food trays and carts, handrails, IV poles, sinks, faucets, shower and lavatory components, work surfaces, door handles, grab bars, computer keyboards, equipment adjustment knobs, and face plates. Copper’s antimicrobial properties are purported to remain effective for the product’s lifetime, and they do not rely on coatings or impregnated surfaces, which may wear away or wash away, limiting their lifetime of service. The manufacturer association claims that copper touch surfaces continuously reduce bacterial contamination, achieving 99.9% reduction of gram-negative and gram-positive bacteria within 2 hours of exposure, and that the surface delivers continuous antibacterial activity between routine cleaning and sanitizing steps. Antimicrobial copper consists of copper alloys such as brass and bronze, copper nickels, and copper-nickel-zincs. Manufacturers intend these alloys to have strength comparable to stainless steel. Copper alloys are purported to be durable; natural tarnishing does not impair the surface’s efficacy, and copper touch surfaces have been deemed to not be harmful to people or the environment.

The manufacturer purports that copper surfaces exert their antibacterial activity in two sequential steps. First, antimicrobial copper is purported to disrupt the integrity of bacterial cell membranes through oxidation and disrupt physiologic functions such as electrostatic potential. Second, antimicrobial copper ions are purported to penetrate compromised cells and alter cell metabolism by interacting with numerous enzymes crucial for normal metabolic activity. The use of antimicrobial copper is intended to supplement and not substitute for standard infection control practices, and users are advised to continue to follow all current infection control practices. Antimicrobial copper is commercially available in certain hospital settings, such as on door knobs and door push plates. Thirteen companies are positioning to manufacture products containing the Antimicrobial Copper mark.

Antimicrobial Copper is the only hospital touch surface with a U.S. Environmental Protection Agency (EPA) public health registration, allowing the manufacturer to claim that copper surfaces can kill specific bacteria (Staphylococcus aureus, methicillin-resistant S. aureus [MRSA], vancomycin-resistant Enterococcus [VRE], Enterobacter aerogenes, Pseudomonas aeruginosa, and Enterobacter cloacae, and a range of bacteria, including some multidrug-resistant pathogens. Antimicrobial copper surfaces interact with microbes, killing specific bacteria, disrupting cell integrity, and altering cell physiology. The use of antimicrobial copper surfaces in healthcare settings is supported by evidence of its effectiveness in reducing hospital-acquired infections, improving patient outcomes, and reducing healthcare costs.
*Escherichia coli* O157:H7) that cause infections and pose a threat to human health. Although the manufacturer association makes no claims of efficacy against other organisms, the literature has shown that the copper might also be effective against other viruses, bacterial, and fungal pathogens. More than 350 antimicrobial copper alloys exist, such as brass and bronze, that are EPA-registered public health antimicrobial products available to address various practical and aesthetic demands.

The additional cost of manufacturing a copper sink for a hospital room is estimated at $40 to $60 each, which might be considered marginal considering the cost for a hospital sink, which is approximately $7,500. Additionally, copper rails are expected to add approximately $100 to the cost of a standard $30,000 hospital bed. According to the manufacturer, equipping each U.S. hospital room with antimicrobial copper products could cost from $1.5 billion to $2.5 billion, and a return on investment might be realized within 1.0 to 1.5 years after implementation.

An analysis of antimicrobial copper touch surfaces compared with standard surfaces in the ICUs of three U.S. hospitals revealed that the median microbial burden observed on copper surfaces was 97% less than on control surfaces and a significant reduction (40.4%) in the number of infections reported in patients treated in copper-fitted rooms.

In another analysis, copperized (Cu) objects (n=282) in 32 ICU rooms and non-Cu objects (n=288) in 27 ICU rooms were sampled to examine the ability of antimicrobial copper to lower the microbial burden (MRSA and/or VRE) on commonly touched objects (bed rails [99.99% Cu alloy], tray tables [90% Cu alloy], chair arms [90% Cu alloy], call buttons [70% to 95% Cu alloy], monitors [90% Cu alloy], and IV poles [75% to 95% Cu alloy]) and mitigate the acquisition of HAIs. Use of copper significantly reduced the total mean microbial burden of the ICU room by 87.4% (p=0.003). Copper was also effective in reducing the mean microbial burden on four of the six objects (bedrails [99%, p=0.0003], chair arms [38%, p=0.11], call buttons [90%, p=0.003], and IV poles [67%, p=0.11]. Use of copper showed no reduction in the mean microbial burden on tray tables or monitors. *Staphylococcus* was the predominant organism isolated from each object regardless of the surface composition and comprised 78.7% of the mean microbial burden of Cu rooms and 55.5% of non-Cu rooms. According to investigators, MRSA and VRE were frequently isolated from non-Cu objects, but were not isolated from Cu objects.

Another study examined the ability of copper trays and arms on phlebotomy chairs to reduce mean microbial burden compared with standard materials. "Microbial burden was decreased on phlebotomy chairs fitted with copper trays and arms. No such reduction was found on standard chairs. The antimicrobial activity of the copper arms of the chairs also created a microbiidal "halo effect," evident in the reduction of bacteria on adjacent, noncopper, surfaces of the chairs."

In a crossover study in an acute medical ward, a toilet seat, set of tap handles, and a ward entrance door push plate, each containing copper, were compared with equivalent standard, noncopper items in the same ward. Samples were taken once weekly for 10 weeks; after 5 weeks, the copper-containing and noncopper items were interchanged. The median microbial burdens of copper-containing items were from 90% to 100% lower than their control equivalents. All but one item sampled had a statistically significant reduction in microbial burden.

**Clinical Pathway at Point of This Intervention**

ICUs typically contain stainless steel and plastic surfaces that are disinfected with standardized terminal cleaning procedures when patients are discharged from a room. Antimicrobial copper touch surfaces might help prevent the accumulation of pathogens between cleanings.
Overall, experts commenting on this intervention stated that antimicrobial copper touch surfaces might have a significant impact on reducing HAIs and associated morbidity, mortality, and costs. Although a significant capital investment may be required to retrofit frequently touched surfaces in ICUs, the intervention is expected to quickly provide durable cost-savings and improved patient outcomes. Except for a one-time disruption in patient management, use of antimicrobial copper is not expected to alter hospital operations. Based on this input, our overall assessment is that this intervention is in the higher end of the high potential impact range.

Results and Discussion of Comments

Seven experts, with research, clinical, and health systems backgrounds, offered comments on this intervention. Overall, the experts agreed that HAIs lead to significant morbidity, mortality, and costs in health care facilities. The unmet need to reduce these infections is significant because current infection control practices and education have not lowered these rates adequately in many cases. Overall, the experts stated, use of copper surfaces might be able to address the unmet need by reducing the frequency of HAIs.

The experts stated that implementation of copper touch surfaces in ICUs would create only a minimal one-time disruption in infrastructure and patient management when some rooms would be unavailable to accommodate retro-fitting with copper surfaces. Implementing copper surfaces into new infrastructure and equipment purchased is expected to be easier than retrofitting existing surfaces.

The experts believe that use of antimicrobial copper surfaces in ICUs would be widely accepted by both patients and physicians because this intervention might be a simple nontoxic way help to solve a complex and burdensome problem in health care. One expert representing a clinical perspective stated that physicians are more likely to accept this intervention if they will not personally bear the cost of fitting facilities with antimicrobial copper. Experts stated that patients will likely accept an intervention that is expected to improve their health outcome. One expert representing a health systems perspective stated that acceptance by clinicians or patients will be secondary to acceptance by health systems administrators, whose acceptance will be crucial to implement the intervention. The experts also stated that although a one-time capital investment for new copper fixtures (which are slightly more expensive than current fixtures) is required, they are likely to be cost-saving within a year or two because extended ICU admissions can be among the most expensive occurrences in health care.
Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

In 2006, an estimated 300,000 U.S. hospitalizations were complicated by Clostridium difficile infections (CDIs), with estimated costs of $431 million to $3 billion annually. Inappropriate use of antibiotics can result in a disturbance of the normal bacterial flora of the colon, colonization with C. difficile, and release of toxins that cause mucosal inflammation and damage. Patients infected with C. difficile typically have watery diarrhea, fever, loss of appetite, nausea, and abdominal pain/tenderness. Chronic and relapsing CDIs are increasingly common and a challenge to treat effectively; about 20% of patients have a recurrence. Although vancomycin or metronidazole is typically used after a second CDI recurrence, up to 60% of these patients develop further recurrence after vancomycin therapy is stopped, which suggests that other therapeutic options are needed.

Colonoscopic fecal bacteriotherapy, or fecal microbiota transplantation (FMT), is intended to recolonize a patient’s intestinal flora with beneficial bacteria that will “crowd out” or otherwise make the environment in the bowel unfavorable for C. difficile colonization. For the colonoscopic FMT procedure, healthy donors submit fresh stool on the day of the procedure, and it is mixed with saline into a solution and tested for pathogens, including hepatitis A, B, and C; syphilis; and HIV (the exact pathogens depend on the center). Centers collecting and processing the stool also typically screen transplant recipients for similar diseases to prevent disease transmission. Prospective donors are excluded if they recently used antibiotics or had a bout of diarrhea. Once the fecal-saline solution is prepared and tested, it is introduced into the right cecum in the intestine by a gastroenterologist using a colonoscope, and the rest is introduced distally as the colonoscope is withdrawn. Approximately 300 to 500 mL are infused into the patient; the dose varies by patient weight. Typically, this procedure is required only once in a patient. Other fecal transplantation procedures have also been reported using enemas and nasogastric tubes.

In the largest analysis to date from five treatment centers across the U.S., FMT was reported to be 91% effective in patients (n=77) with recurrent CDI. The mean age of the patient population was 65 years, and 40% of these patients were hospitalized, homebound, or in a specialized nursing facility at the time of the procedure. The median time of illness before therapy was 11 months, and the mean number of courses of antibiotic therapy was five before treatment. Patients treated with FMT had a mean time to resolution of diarrhea of 6 days. During long-term followup, only patients who were treated later with antibiotics (n=8) had a CDI recurrence. Two of these patients were successfully treated again with FMT. In addition, 53% of patients in this study stated they would have preferred FMT as their first-line treatment.

In another trial, patients (n=70) with recurrent CDI were treated with colonoscopic FMT. All patients had a favorable response except those infected with strain type 027 CDI, who had an 89% favorable response rate. Four patients who did not respond to FMT each had a preexisting serious condition, caused by a chronic diarrhea or comorbidity, and all subsequently died of colitis. Within the first year after FMT, four patients previously treated had a relapse after later treatment with antibiotics. Two of these patients were successfully treated with another FMT, and two were treated with antibiotics for CDI.

In another trial, prospective data were collected from three different centers performing FMT on 37 patients with recurrent CDI. Patients received one or two FMTs. Ninety-two percent (75% to 100%) of patients were cured. Two experienced a recurrence 5 to 12 months after receiving subsequent antibiotic treatment and were successfully retreated with FMT. One noncured patient died after 1 month due to toxic megacolon. He had refused the suggested operative treatment before the FMT.
In a retrospective study of 12 consecutive patients (9 women and 3 men, mean age 66 years) with refractory/recurrent CDI who were symptomatically ill for a mean of 351 days before colonoscopic FMT, 100% experienced an immediate and durable clinical response to FMT. No adverse events were reported from FMT.125

FMT is being implemented in a limited number of research and gastrointestinal specialty centers. This medical procedure can be readily adopted by clinicians and is not subject to FDA regulation because the material is collected and prepared in the institution.

Four trials are under way and registered in the National Clinical Trials Database and the International Clinical Trials Registry Platform to assess colonoscopic FMT in patients with recurrent, relapsing, or refractory CDI.126-129 In one phase II/III, randomized, open-label trial, patients with recurrent CDI (n=126) will be treated with either 2 weeks of oral vancomycin pretreatment followed by a single FMT procedure administered by rectal enema or 2 weeks of oral vancomycin pretreatment followed by a 6-week taper of oral vancomycin. Patients will be assessed for CDI recurrence up to 120 days following treatment. This trial is expected to be completed in December 2013.126

In another phase II, randomized, double blind, crossover trial, patients with recurrent or refractory CDI (n=120) will be treated with either three FMT retention enemas (days 1, 5, and 12) and 14 days of oral placebo or oral vancomycin for 14 days with a saline enema (days 1, 5, and 12).127 Patients will be assessed for clinical cure, treatment failure, and relapse rate over 14 days. This trial is expected to be completed in June 2013.127

In a third, nonrandomized, open-label trial, patients with recurrent CDI who have not responded to standard therapy (n=30) will be treated with “synthetic stool” or pure cultures of intestinal bacteria derived from healthy donor stool administered by rectal enema.128 Patients will be assessed for clinical cure for up to 6 months after treatment. This trial is expected to be completed in January 2013.128

Finally, in a randomized, single blind trial, patients with recurrent CDI (n=120) will be treated with oral vancomycin for 14 days, oral vancomycin for 14 days, and bowel lavage with KleanPrep on day 4, or oral vancomycin for 4 days followed by bowel lavage and FMT administered via nasoduodenal tube on day 5.129 Patients will be assessed for diarrhea and C. difficile toxin in stool 10 weeks after therapy. No completion date was reported for this trial.129

Specific cost information on the procedure is scarce because it has been performed infrequently by a limited number of clinicians at a small number of centers. Reported costs associated with screening donor blood and stool for contagious agents, preparation of the donor fecal sample, and placement of a nasogastric tube or retention enema tube can exceed $2,500. If the procedure is done by colonoscopy, the average cost of colonoscopy is about $3,000. Screening, collection, and preparation of the stool would be additional costs.

Clinical Pathway at Point of This Intervention

According to CDC, once CDI is confirmed in patients, they are taken off the antibiotic that created the environment for the infection to occur, and in some patients (20%, within 2 to 3 days) the infection may resolve without further treatment. If it does not, the patient may be treated with either oral metronidazole or vancomycin for 10 days.130 FMT is intended to treat recurrent CDI.
Overall, experts concluded that results from FMT studies completed thus far are very promising. They thought that the procedure has significant potential to address the unmet need for effective treatment for CDI recurrence by providing a relatively low-cost, effective treatment, preventing antibacterial resistance, reducing the probability of CDI transmission, and lowering CDI-associated mortality. However, experts were eager to see larger studies to better determine the role of FMT in clinical practice and whether it should be first-line therapy for CDI. Experts noted that several societal barriers to acceptance of the procedure may slow diffusion; however, they also noted that hesitation on the part of patients might be mitigated by poor quality of life and ongoing illness in patients with recurrent CDI. Experts stated clinicians will have greater acceptance of the procedure once donor screening, testing, and transplant processing protocols are established. Experts thought that FMT has high potential to significantly improve health outcomes in patients with difficult-to-treat, recurrent CDI. As the potential role of this intervention continues to be defined by clinicians using it, the procedure’s unconventional and controversial nature could continue to provide catchy headlines for the media, they opined. Based on this input, our overall assessment is that this intervention is in the higher end of the high-potential-impact range.

Results and Discussion of Comments

Seven experts, with clinical, research, health systems, and health administration backgrounds, provided comments on this intervention.\(^{131-137}\) All experts concurred that recurrent CDI causes great morbidity, mortality, and costs to patients and the health care system. Emerging antibacterial resistance associated with these infections represents an important unmet need. A general consensus arose among the experts that FMT has the potential to address the unmet need for effective treatment for recurrent CDI without the use of antibiotics, which could lead to a significant impact on health outcomes and quality of life. In general, the experts accepted the underlying theory of FMT and were somewhat certain that it could be highly effective, although larger trials will be needed to bear this out.

The experts mentioned that health care facilities generally have the staffing and equipment needed to perform the procedure and expect minimal disruptions to infrastructure and patient management. Potential disruptions cited would include shortened duration of inpatient stays, reduction in ICU admissions for toxic megacolon, and transition from inpatient to outpatient treatment with FMT.

Experts generally viewed the procedure as cost-neutral or cost-saving compared to multiple failed courses of antibiotics and resultant complications. The experts expected clinicians to accept the procedure increasingly as donor selection, screening, and transplant processing protocols become standardized. Patients with long-term CDI recurrence, as well as their treating physicians, might be eager to try any therapy that has a high likelihood of efficacy. Psychological factors or religious beliefs may also preclude some patients from seeking the treatment. One expert representing a clinical perspective thought that even a different name for the procedure might be needed to increase acceptance.
**Fidaxomicin (Dificid) for Treatment of Clostridium difficile Infection**

Fidaxomicin (Dificid™, Optimer Pharmaceuticals, Inc., San Diego, CA) is a narrow-spectrum, oral macrolide antibiotic that is microbiologically active against *C. difficile*. Fidaxomicin inhibits RNA polymerase, a bacterial enzyme, resulting in the death of the bacteria; the drug is also purported to inhibit bacterial toxin production. Fidaxomicin is purported to be poorly absorbed by the body, allowing the intervention to exert its activity in the gastrointestinal tract. In addition, fidaxomicin is purported to be highly selective to *C. difficile*, allowing it to leave the normal intestinal flora intact.

A combined analysis of two randomized controlled trials with identical protocols comparing oral fidaxomicin (200 mg twice daily) to oral vancomycin (125 mg 4 times daily) for 10 days in adults with acute CDI symptoms and a positive stool toxin test (n=1,105) presented results of cure rates of 91.9% and 90.2% with fidaxomicin and vancomycin, respectively. CDI recurrence rates were significantly lower in patients treated with fidaxomicin (13%) compared with vancomycin (24.6%; p<0.001). Global cure rates were 78.6% and 66.4%, respectively (p<0.001), in patients treated with fidaxomicin and vancomycin. Adverse events were similar in both trials and not different among the treatments.

In another analysis, patients (n=128) with one prior CDI episode and recurrence within 3 months were treated with oral fidaxomicin (200 mg twice daily) or vancomycin (125 mg 4 times daily) for 10 days. After treatment, 19.7% of patients receiving fidaxomicin experienced another recurrence compared with 35.5% of patients receiving vancomycin (p=0.045), a 45% reduction in repeat recurrent events when patients were treated fidaxomicin.

In a combined analysis of two phase III, randomized, controlled, blinded trials, adults with active CDI were randomly assigned to receive fidaxomicin (200 mg twice daily) or vancomycin (125 mg 4 times daily) for 10 days. Fidaxomicin was noninferior for clinical cure and superior for reducing CDI recurrence compared with vancomycin. In an intent-to-treat analysis of the combined data of patients (n=1,164), fidaxomicin was reported to reduce persistent diarrhea, recurrence, or death by 40% (p<0.0001) compared with vancomycin overall through day 40. Investigators stated, “A 37% (p=0.037) reduction in persistent diarrhea or death was evident through day 12 (heterogeneity p=0.50 vs. 13-40 days), driven by 7 (1.2%) fidaxomicin vs. 17 (2.9%) vancomycin deaths through 12 days (exact p=0.06).” Low albumin and eosinophil counts and the use of metronidazole/vancomycin before randomization were risk factors for persistent diarrhea/death through 12 days, and CDI in the previous 3 months was a risk factor for relapse (all p<0.01).

In June 2011, FDA approved fidaxomicin for treating *C. difficile*-associated diarrhea (CDAD). It is taken twice daily for 10 days. Optimer Pharmaceuticals announced a 2-year agreement with Cubist Pharmaceuticals, Inc. (Lexington, MA), to copromote fidaxomicin under the brand name Dificid in the U.S. For the manufacture and supply of fidaxomicin, Optimer entered into an agreement with Biocon (Bangalore, India) in 2010. According to one U.S.-based online pharmacy, a 10-day course of fidaxomicin costs about $3,625. A 10-day course of vancomycin costs about $1,400. Our searches of 11 representative private third-party payers that provide online medical coverage policies (i.e., Aetna, Anthem, Blue Cross/Blue Shield Alabama, Blue Cross/Blue Shield Massachusetts, CIGNA, HealthPartners, Humana, Medica, Regence, United Healthcare, Wellmark) found 7 that list coverage determinations for fidaxomicin for treating CDAD. Six third-party payers cover fidaxomicin for members with CDAD. However, preauthorization is typically required, and fidaxomicin often has tier-3 or -4 formulary status.
Clinical Pathway at Point of This Intervention

Two interventions have been the standard treatment options for CDI over the past 25 years. Mild to moderate CDI is typically treated with metronidazole (Flagyl®, Pfizer, Inc., New York, NY), though this is only given for the initial episode because of neurotoxicity concerns. For more severe CDI, vancomycin (Vancocin® , ViroPharma Inc., Exton, PA), currently the only FDA-approved antibiotic for treating CDI, is the standard treatment, either alone or in combination with metronidazole. Fecal microbiota transplantation is also emerging as a CDI treatment. Fidaxomicin offers an alternative antibiotic treatment for CDI, with the possibility of less recurrence than is seen with vancomycin.

Figure 7. Overall High Impact Potential: Fidaxomicin for treatment of *C. difficile* infection

Experts noted that CDI persistence is common and costly, with high morbidity and mortality in patients with recurrent infection, which responds poorly to antibiotic therapy. Experts thought that the lack of new medications for effective treatment of recurrent CDI would make welcome a new option that reduces recurrence rates. In addition, experts had some concern that treating patients with vancomycin for CDI might make them more likely to develop vancomycin-resistant enterococcus infections. Fidaxomicin could be used to ease some of those concerns, experts believed, because it has been shown to have comparable efficacy to vancomycin with fewer CDI recurrences, which might improve quality of life for many patients by shortening the infection duration. Although fidaxomicin is more expensive than vancomycin, experts thought that the antibiotic could reduce costs associated with the prevention of CDI recurrence. However, diffusion of fidaxomicin as a first-line treatment will depend largely on the drug’s formulary status at third-party payers. Based on this input, our overall assessment is that this intervention is in the higher end of the high-potential-impact range.

Results and Discussion of Comments

Seven experts, research, clinical, and health systems backgrounds, offered perspectives on this intervention. The experts agreed that CDI can be prolonged and costly, with high morbidity and mortality in patients with recurrent infection, which responds poorly to antibiotic therapy. One expert representing a clinical perspective stated that there has been a lack of new medications for the treatment of recurrent CDI. Additionally, a need exists for improved tolerability of CDI treatment. One clinical expert also expressed concern about using vancomycin to treat CDI because of the possibility that patients may develop vancomycin-resistant enterococcus infections. Based on current evidence, fidaxomicin might have comparable efficacy to vancomycin with fewer recurrences, which could improve quality of life for many patients.

The experts did not expect fidaxomicin to cause a significant disruption to health care delivery infrastructure or patient management because one antibiotic will replace another. However, they thought that changes could include less demand on inpatient treatment facilities and staff because of a reduction in recurrent infections. Reduced demand on outpatient facilities and staff might also be observed because of shorter durations of infection. All the experts agreed that although fidaxomicin is
twice as expensive as vancomycin, the antibiotic’s costs are expected to be offset by a reduced frequency of recurrent infections, which would save significant costs.
Xpert MTB/RIF Test for Simultaneous Detection and Drug Sensitivity Testing of *Mycobacterium Tuberculosis*

According to the World Health Organization, tuberculosis infection (TB) is considered to be highly underdiagnosed. This is a direct result of current TB testing methods, which require weeks to deliver a definitive result. During that time, patients are untreated or placed on ineffective therapies. These patients may also continue to spread TB to others in the community, creating a significant public health concern.\(^\text{162}\)

The *Mycobacterium tuberculosis*/rifampicin test (Xpert MTB/RIF, Cepheid, Sunnyvale, CA) is a nucleic-acid-based test run on Cepheid’s GeneXpert® real-time polymerase chain reaction (PCR) system.\(^\text{162}\) The test simultaneously detects the presence of *M. tuberculosis* complex species and determines whether the identified bacterium is susceptible to rifampicin.\(^\text{163}\) In the assay, a real-time hemi-nested PCR reaction is performed to amplify and detect a portion of the *rpoB* gene, a genetic marker that is specific for a subunit of an RNA polymerase that is essential for TB viability.\(^\text{162}\) The antibiotic activity of the first-line TB drug rifampicin targets the subunit encoded by the *rpoB* gene to inhibit the RNA polymerase, inhibiting bacterial survival.\(^\text{162}\) Research has demonstrated that the portion of the *rpoB* gene amplified in the Xpert MTB/RIF assay harbors mutations in the majority of rifampicin-resistant TB strains.\(^\text{164}\)

In the assay, the detection of TB DNA in the patient sample is accomplished by five separate real-time PCR fluorescent probes, which are specifically activated in the presence of amplified *rpoB* DNA and detected by the GeneXpert system.\(^\text{163}\) Each of the five probes overlaps a different site known to be mutated in rifampicin-resistant TB if rifampicin resistance can be determined based on the binding signal given from the probes.\(^\text{163}\)

To perform the test, a technician first treats a patient sputum sample with a solution containing sodium hydroxide and isopropanol (isopropyl alcohol) to reduce the viability of any *M. tuberculosis*, thereby preventing contamination.\(^\text{162,163}\) Subsequent processing and detection are performed on the GeneXpert system using a single-use, closed Xpert MTB/RIF cartridge that contains all the reagents necessary for testing.\(^\text{162,163}\) The procedure’s automated nature and the fact that it does not require handling of PCR amplicons are intended to ensure optimal accuracy of the assay by limiting interoperator variability and reducing the potential for false positives caused by amplicon contamination.\(^\text{163}\) The assay is intended to yield results for both the presence of *M. tuberculosis* and antibiotic resistance for positive samples in about 2 hours.\(^\text{162}\) Full drug susceptibility testing would still need to be performed in patients with rifampicin-resistant TB for a clinician to fully determine an effective treatment regimen.

In a large multicenter trial, patients (18 years of age or older) suspected of having TB or multidrug-resistant TB (n=6,648) presenting with cough lasting at least 2 weeks were tested for TB using Xpert MTB/RIF as well as culture and microscopy detection methods. The investigators reported “One-off MTB/RIF testing detected 933 (90.3%) of 1033 culture-confirmed cases of tuberculosis, compared with 699 (67.1%) of 1041 for microscopy. MTB/RIF test sensitivity was 76.9% in smear-negative, culture-positive patients (296 of 385 samples), and 99.0% specific (2846 of 2876 non-tuberculosis samples).” The sensitivity and specificity of the MTB/RIF test for rifampicin resistance were 94.4% and 98.3%, respectively. As observed with microscopy, MTB/RIF test sensitivity was not significantly lower in patients with co-infected with HIV. Median time to detection of TB was 0 days for the MTB/RIF, 1 day for microscopy, 30 days for solid culture, and 16 days for liquid culture. Use of the MTB/RIF test reduced the median time to treat patients with smear-negative TB from 56 days to 5 days.\(^\text{165}\)
In an international clinical trial, three sputum samples were collected from patients suspected of having TB or drug-resistant TB (n=1,730). Among culture-positive patients, the Xpert MTB/RIF test gave a positive TB result for 551 of 561 smear-positive patients (98.2%) and for 124 of 171 smear-negative patients (72.5%). Additionally, among 609 culture-negative patients, the Xpert MTB/RIF test correctly identified 604 patients as negative for TB infection (99.2%). As for susceptibility testing, compared with conventional culture-based susceptibility testing, the Xpert MTB/RIF test correctly identified 200 of 205 patients with TB as having a rifampicin-resistant infection (97.6%) and 504 of 514 patients with TB as having a rifampicin-sensitive infection (98.1%).

In an additional study, Xpert MTB/RIF was compared to culture and microscopy detection methods using samples from pediatric patients with suspected TB (n=164). Xpert MTB/RIF detected 100% of the smear-positive cases and 66.6% of culture-positive cases that were smear negative. In the per-sample analysis, Xpert displayed a similar sensitivity compared with culture methods, and detected 3-fold more confirmed TB cases than microscopy in a similar amount of time. Four additional culture-negative cases with clinical tuberculosis (8.5%) were diagnosed by Xpert MTB/RIF. Xpert MTB/RIF demonstrated 100% specificity when TB was reliably excluded; accuracy was not affected by HIV infection in these patients.

Cepheid has obtained a Conformité Européenne (CE) mark for use of the test in Europe. The test is available in the U.S. as a research-use-only reagent. The manufacturer expects to file for U.S. regulatory approval in 2012, with an expected launch date of 2013–2014. Pricing for the Xpert MTB/RIF test is not available; however, other test-cartridge-based assays running on the GeneXpert system cost approximately $20 per assay. Additionally, to run the Xpert MTB/RIF test, a facility would have to have a GeneXpert system, which could represent a capital equipment purchase of more than $100,000 for higher throughput versions. According to one source, standard basic testing for TB costs about $20–$40, and more advanced testing to determine rifampicin resistance can add another $20–$30.

Clinical Pathway at Point of This Intervention

A patient initially presents with symptoms that indicate a possible case of pulmonary TB based on the patient’s medical history, physical examination, symptoms, TB infection test results (e.g., tuberculin skin test, QuantiFERON-TB Gold test), and/or chest x-ray results. The current recommended diagnostic procedure for laboratory confirmation of TB is to obtain a respiratory sputum sample from the patient and test the sample simultaneously with a nucleic acid amplification test, an acid-fast bacteria smear test, and liquid or solid media culture. The Xpert MTB/RIF test would be used in place of current nucleic acid amplification tests. In addition to identifying the presence of TB, the Xpert MTB/RIF test would also give a preliminary indication of potential antibiotic resistance, which would normally be determined following a positive culture isolate by assaying the isolate’s in vitro susceptibility to antibiotics.
Figure 8. Overall High Impact Potential: Xpert MTB/RIF test for detection and drug sensitivity testing of *M. Tuberculosis*

Overall, experts thought that the Xpert MTB/RIF test has potential to be a rapid, sensitive, and specific diagnostic that could address the unmet need for more rapid diagnosis and better initial management of TB. If it does show sufficient efficacy, they thought, it has potential to improve patient health outcomes and reduce the spread of TB. By knowing the patient’s TB status when he or she leaves the physician’s office, experts noted, more appropriate treatment could be given, and proper infection control measures could be implemented. However, experts noted that one limitation of the Xpert MTB/RIF test is that it tests for resistance only to rifampin, which is a common first-line antibacterial agent. Susceptibility to other agents would still have to be guided by traditional testing methods. Nevertheless, the Xpert MTB/RIF test could replace other PCR methods of detection and provide an improved approach to diagnosis and treatment for smaller health care facilities, such as rural or public access clinics, which might have problems with followup. Based on this input, our overall assessment is that this intervention is in the moderate high-potential-impact range.

**Results and Discussion of Comments**

Seven experts, with research, clinical, and health systems backgrounds, offered perspectives on this intervention. Overall, experts concurred that current TB diagnostic methods are lengthy, taking days to weeks to confirm or rule out the presence of TB and antibiotic susceptibility. This presents a significant unmet need for more rapid diagnostic testing to direct appropriate therapy and implement infection control measures, particularly when dealing with immunosuppressed individuals. Experts agreed that the test’s underlying theory is sound and that it does not differ significantly from current molecular methods, other than the faster turnaround time. All but one expert thought the time saved in diagnosis using the Xpert MTB/RIF test could improve patient health outcomes. The remaining expert had a research perspective and was more skeptical of the test’s potential.

In general, the experts though the Xpert MTB/RIF test would not make a large impact on how the disease is treated or diagnosed but that it would allow current treatment strategies to be employed earlier and, therefore, potentially reduce transmission. One expert representing a clinical perspective stated that the most important aspect in diagnosing TB is still clinical suspicion of TB.

With regard to impact on patient management and care setting, the availability of the Xpert MTB/RIF test would allow smaller offices to do their own testing, which could lead to decentralization of testing, some experts thought. A greater availability of testing centers might also improve access to care and potentially reduce health disparities and promote health by avoiding transmission of the infection. Although experts expected impact on staffing and training to be minimal, a significant capital investment of $100,000 is required to purchase the GeneXpert system if the facility has not purchased it for other testing. The per-patient test cost might be higher than for current methods but would not be prohibitive (about $50 per test). Faster turnaround time and high predictive values directing rapid treatment are expected to be readily accepted by patients and clinicians with little controversy.
References


34. Expert Commenter 419. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS287 - Telaprevir for treatment of chronic hepatitis C infection. 2012 Apr 10 [review date].


51. Expert Commenter 524. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS723 - Collaborative care model (HITIDES) for treatment of depression secondary to HIV. 2012 Apr 16 [review date].

52. Expert Commenter 712. (External, Clinical). Horizon Scanning Structured Comment Form. HS723 - Collaborative care model (HITIDES) for treatment of depression secondary to HIV. 2012 Apr 23 [review date].

54. Expert Commenter 403. (ECRI Institute, Health Devices). Horizon Scanning Structured Comment Form. HS723 - Collaborative care model (HITIDES) for treatment of depression secondary to HIV. 2012 Apr 16 [review date].

55. Expert Commenter 603. (External, Clinical). Horizon Scanning Structured Comment Form. HS723 - Collaborative care model (HITIDES) for treatment of depression secondary to HIV. 2012 Apr 23 [review date].

56. Expert Commenter 426. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS723 - Collaborative care model (HITIDES) for treatment of depression secondary to HIV. 2012 Apr 16 [review date].

57. Expert Commenter 433. (PRI, Health Systems/Administration). Horizon Scanning Structured Comment Form. HS723 - Collaborative care model (HITIDES) for treatment of depression secondary to HIV. 2012 Apr 18 [review date].


75. Expert Commenter 412. (ECRI Institute, Health Devices). Horizon Scanning Structured Comment Form. HS508 - Truvada for prevention of HIV infection. 2011 Apr 8 [review date].

76. Expert Commenter 414. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS508 - Truvada for prevention of HIV infection. 2011 Apr 5 [review date].

77. Expert Commenter 427. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS508 - Truvada for prevention of HIV infection. 2011 May 4 [review date].


111. Expert Commenter 1178. (ECRI Institute, SELECT Group). Horizon Scanning Structured Comment Form. HS1180 - Copper surfaces in the intensive care unit for prevention of hospital acquired infections. 2012 Apr 19 [review date].


114. Expert Commenter 429. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS1180 - Copper surfaces in the intensive care unit for prevention of hospital acquired infections. 2012 Apr 19 [review date].

unit for prevention of hospital acquired infections. 2012 Apr 19 [review date].


130. Frequently asked questions about clostridium difficile for healthcare providers. [internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); [updated 2010 Nov 25]; [accessed 2011 Jan 3]. [8 p]. Available:
131. Expert Commenter 396. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS283 - Fecal transplantation to treat recurrent C. difficile infection. 2012 Apr 16 [review date].


134. Expert Commenter 1178. (ECRI Institute, SELECT Group). Horizon Scanning Structured Comment Form. HS283 - Fecal transplantation to treat recurrent C. difficile infection. 2012 Apr 19 [review date].


136. Expert Commenter 422. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS283 - Fecal transplantation to treat recurrent C. difficile infection. 2012 Apr 19 [review date].

137. Expert Commenter 938. (External, Health Systems/Administration). Horizon Scanning Structured Comment Form. HS283 - Fecal transplantation to treat recurrent C. difficile infection. 2012 Apr 18 [review date].


160. Expert Commenter 421. (ECRI Institute, Technology Assessment). Horizon Scanning Structured Comment Form. HS749 - Fidaxomicin for treatment of Clostridium difficile infection. 2011 Sep 9 [review date].


168. Introducing Xpert MTB. The only on-demand, rapid Mycobacterium tuberculosis test. Maurens-Scopont (France): Cepheid Europe; 1 p.


and drug sensitivity testing of Mycobacterium tuberculosis. 2011 Feb 3 [review date].
